Skip to content
IMEXP.RU
EAEU HS code

3004 90 000 2 — Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: other: put up in forms or packings for retail sale: other

Other: put up in forms or packings for retail sale: other

Full name

Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: other: put up in forms or packings for retail sale: other

Names come in English where the EU Combined Nomenclature publishes them — chapters, headings and subheadings, whose first six digits are the same Harmonized System; deeper EAEU detail is a machine translation, marked as such. Official texts — tariff notes, measures, lists and classification rulings — are the original: customs and your broker go by that wording. Where we show a machine translation of them, it is marked; where our quality check rejected one, the Russian stays.

Machine translation. The original is the Russian text of the EAEU tariff, and customs goes by it; this translation is for understanding only and has no legal force.

Duty rate
3%

This is the base rate. A tariff quota, a preference for the country of origin and a tariff exemption lower it; anti-dumping and special duties are paid on top of it

EEC Council Decision No. 80 of 14.09.2021

Supplementary unit
Not applicable
Requirements and measures
6

None: russian bans and restrictions, recycling fee, export control, trade defence measures — duty on top of the tariff, tariff quota.

Whether a measure applies to your goods depends on their characteristics and the shipping documents

VAT
22%

The general import rate in Russia: Tax Code of Russia, Art. 164(3) (Federal Law No. 425-FZ of 28.11.2025). This code is not named on the 10% VAT list (Decree No. 908) or the exemption list (No. 1042). The list of medical goods No. 688 is not checked here.

Product reference in Word (in Russian)

Duties, taxes, fees, bans, permits and controls in one free file.

Import into Russia

Import reference

Export from Russia

Export reference

Import into Russia

Payments on import

Duty for this code: 3%. On top of the duty, on import into Russia you pay VAT of 22% of the customs value including the duty (Article 160 of the Tax Code) and the customs processing fee — a fixed amount by value band. Customs value: the price of the goods, delivery to the border, local costs.

The CCT rate applies from Mar 8, 2026: Решение Совета ЕЭК № 13 от 30.01.2026.

How the rate for this code has changed
Customs fee scale by customs value, 2026
  • from 0 to 200,000 ₽1,231 ₽
  • from 200,000 to 450,000 ₽2,462 ₽
  • from 450,000 to 1,200,000 ₽4,924 ₽
  • from 1,200,000 to 2,700,000 ₽13,541 ₽
  • from 2,700,000 to 4,200,000 ₽18,465 ₽
  • from 4,200,000 to 5,500,000 ₽21,344 ₽
  • from 5,500,000 to 10,000,000 ₽49,240 ₽
  • over 10,000,000 ₽73,860 ₽

Fee per declaration. Russian Government Resolution No. 1637 of 28.11.2024 as amended by Resolution No. 1638 of 23.10.2025.

Import VAT in EAEU countries

  • Russia22%
  • Kazakhstan16%
  • Belarus20%
  • Armenia20%
  • Kyrgyzstan12%

Standard rate; each country has reduced rates and exemptions for some goods. The duty for the code above is the union one, the same for all

Customs declaration fee

  • Kazakhstan6 MCI per goods declaration, KZT 25,950 in 2026
  • BelarusBYN 50 for goods of chapter 30from Jan 1, 2027: BYN 55
  • ArmeniaAMD 3,500 for clearanceinspection and recording: AMD 1,000 per consignment up to 1 t and AMD 300 per each additional tonne
  • Kyrgyzstan0.4% of the customs valuenot less than 5 and not more than 2,500 calculation units
Calculate the whole deal →Quick payment calculation →

Documents required

A summary across all the lists we check: the document, its legal basis and whether it covers the whole code. Details are in the sections below.

Goods in customs transit may be tracked with a navigation seal: this depends on the route and procedure, not on the code (EAEU Agreement of 19.04.2022, EEC Board Decision No. 84).

Customs declaration hints

Boxes 33, 36, 44, 47

Which codes go into the boxes of the goods declaration for this product. The codes come from the classifiers of Customs Union Commission Decision No. 378. Reliefs, document types and excise depend on the shipment, so such lines carry a condition.

Box 33 · Commodity code

  • 3004900002
  • Сin the second subdivision, if the goods do not fall under the bans and restrictions that apply to the code
  • Мin the second subdivision, if the goods are on the marking list but its requirements do not apply to them
  • Оin the second subdivision, if goods with different names are declared under one code

Box 36 · Preference

  • ОООО-ООFees, duty, excise, VAT: no relief claimed, no excise (dash)

Box 44 · Documents produced

  • 01408Документ об оценке соответствия, предусмотренный законодательством государства – члена Евразийского экономического союза, на территории которого продукция (товар) помещается под таможенные процедуры · Постановление № 2425
  • 01201Ветеринарный сертификат · Решение Коллегии Евразийской экономической комиссии от 20.01.2020 № 13
  • 01011Лицензия на экспорт и (или) импорт товаров · Решение Коллегии ЕЭК № 30, раздел 2.12
  • 01081Заключение (разрешительный документ) на ввоз лекарственных средств · Решение Коллегии ЕЭК № 30, раздел 2.14

Box 47 · Calculation of payments

  • 1010Таможенные сборы за совершение таможенных операций (за таможенное оформление товаров, за таможенное декларирование товаров, за таможенные операции)
  • 2010Ввозная таможенная пошлина (иные пошлины, налоги и сборы, имеющие эквивалентное действие), обязанность по уплате которой возникла с 1 сентября 2010 г.
  • 5010Налог на добавленную стоимость

Completion rules and classifiers: Решение Комиссии Таможенного союза от 20.05.2010 № 257; классификаторы — Решение Комиссии Таможенного союза от 20.09.2010 № 378

Each requirement in detailMedicinal products · Mandatory labelling · Veterinary, plant quarantine and sanitary control · Conformity assessment · How it is certified · EAEU non-tariff regulation

Medicinal products

If the product is a medicinal product for human use, only registered products may be imported (Article 47 of Federal Law No. 61-FZ), they are marked with identification codes (Article 67 of the same law, Government Resolution No. 1556), and import VAT is 10% under the code list of Government Resolution No. 688.

Mandatory labelling

The code is named in the list of goods subject to labelling with identification means. Whether your product must be labelled depends on its name and its OKPD 2 code.

  • Item 77. Лекарственные препараты для ветеринарного применения

    Labelling mandatory from: 1 сентября 2024 г.; 1 марта 2026 г.

Russian Government Order No. 792-r of 28.04.2018 as amended by Orders No. 1765-r of 04.07.2024, No. 249-r of 07.02.2025 and No. 956-r of 27.04.2026. Deadlines and procedures for individual groups are set by Government resolutions on labelling rules.

Veterinary, plant quarantine and sanitary control

Goods fall under supervision by their type and characteristics

  • Sanitary and epidemiological supervision (control)

    rule for the whole chapter 30
    Материалы для изделий (изделия), контактирующих с кожей человека, одежда, обувь; Иная продукция (товары), в отношении которой одним из государств – членов Евразийского экономического союза введены временные санитарные меры

    The list names this code with “ex”: control applies only to goods with this description.

    Решение Коллегии Евразийской экономической комиссии от 17.09.2019 № 154

  • Veterinary control (supervision)

    rule for the whole chapter 30
    Фармацевтическая продукция (для применения в ветеринарии)

    The list names this code with “ex”: control applies only to goods with this description.

    Such goods need a veterinary certificate, and the manufacturing plant must be on the register of third-country establishments. Check the supplier in the register →

    Решение Коллегии Евразийской экономической комиссии от 20.01.2020 № 13

Conformity assessment

May apply

Whether the goods fall under a regulation depends on their name and characteristics. Check them against the list

  • Постановление № 2425Единый перечень продукции: сертификация и декларирование в РФ
    • Кормогризин — declaration of conformity (part of the heading) · ГОСТ Р 57244-2016, ГОСТ 13496.13-2018, ГОСТ 10199-2017

    С 1 сентября 2022 г. декларация о соответствии такой продукции принимается при наличии у изготовителя (продавца) протокола исследований (испытаний) и измерений, проведенных аккредитованной в национальной системе аккредитации испытательной лабораторией (центром).

Checked: the consolidated list of Government Decree No. 2425 and the lists of 42 technical regulations out of 52 adopted. The others have no list by HS code, so see the full list of regulations.

How it is certified

Valid documents in the EAEU unified register for subheading 3004 90: certificates 0, declarations 23.

By technical regulation
ТР ТС 021/201112ТР ТС 022/201112ТР ТС 029/201211ТР ТС 009/201110ТР ТС 024/20111
Schemes
3д141д9The letter after the scheme number shows the form: certification or declaration of conformity.
Manufacturers outside the EAEU
China2France1India1South Korea1Thailand1Türkiye1

Manufacturers of these goods →Check a supplier’s document by its number →

EAEU non-tariff regulation

Unified list of non-tariff measures (EEC Board Decision No. 30 of 21.04.2015). List entries selected by code

  • 2.12licensing regimeon import and export

    Наркотические средства, психотропные вещества и их прекурсоры

    5 list entries

    Оксикодон текодин 14-гидроксидигидрокодеинон; порошке: 48 - 50; масличного мака; циклогептен-5-ил)амино]гептановая кислота; (+)-альфа-метилфенэтиламин 170. Декстрометорфан

  • 2.14licensing regimeon import and exportpartial match

    Лекарственные средства

    1 list entry

    3005 или 3006), состоящие из смеси двух или более компонентов, для использования в терапевтических или профилактических целях, но не расфасованные в виде дозированных лекарственных форм или в формы или упаковки для розничной продажи (кроме используемых для ветеринарии) 5. Лекарственные средства (кроме товаров товарной позиции 3002,

Export from Russia

Documents required

A summary across all the lists we check: the document, its legal basis and whether it covers the whole code. Details are in the sections below.

Customs declaration hints

Boxes 33, 44, 47

Which codes go into the boxes of the goods declaration for this product. The codes come from the classifiers of Customs Union Commission Decision No. 378. Reliefs, document types and excise depend on the shipment, so such lines carry a condition.

Box 33 · Commodity code

  • 3004900002
  • Оin the second subdivision, if goods with different names are declared under one code

Box 44 · Documents produced

  • 01011Лицензия на экспорт и (или) импорт товаров · Решение Коллегии ЕЭК № 30, раздел 2.12
  • 01081Заключение (разрешительный документ) на ввоз лекарственных средств · Решение Коллегии ЕЭК № 30, раздел 2.14
  • 01201Ветеринарный сертификат · Ветеринарные требования страны ввоза

Box 47 · Calculation of payments

  • 1010Таможенные сборы за совершение таможенных операций (за таможенное оформление товаров, за таможенное декларирование товаров, за таможенные операции)

Completion rules and classifiers: Решение Комиссии Таможенного союза от 20.05.2010 № 257; классификаторы — Решение Комиссии Таможенного союза от 20.09.2010 № 378

Classification

Where it sits in the nomenclature

Section VI. Products of the chemical or allied industries

  1. 30Pharmaceutical products
  2. 3004Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses "incl. those for transdermal administration" or in forms or packings for retail sale (excl. goods of heading 3002, 3005 or 3006)
  3. 3004 90Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes, put up in measured doses "incl. those for transdermal administration" or in forms or packings for retail sale (excl. containing antibiotics, hormones or steroids used as hormones, alkaloids, provitamins, vitamins, their derivatives or antimalarial active principles)
  4. 3004 90 00Other
  5. 3004 90 000 2you are here

Compare the description of your goods with the neighbouring codes on the subheading line above.

Explanatory notes to heading 3004 8 paragraphs

Machine translation from Russian. The original is the EEC explanatory note, and that is what a classification dispute is argued from; the translation is for understanding and has no legal force.

3004 Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: 3004 10 – containing penicillins or derivatives thereof, with a penicillanic acid structure, or streptomycins or their derivatives 3004 20 – other, containing antibiotics: – other, containing hormones or other products of heading 2937: 3004 31 – – containing insulin 3004 32 – – containing corticosteroid hormones, their derivatives or structural analogues 3004 39 – – other – other, containing alkaloids or derivatives thereof: 3004 41 – – containing ephedrine or its salts 3004 42 – – containing pseudoephedrine (INN) or its salts 3004 43 – – containing norephedrine or its salts 3004 49 – – other 3004 50 – other, containing vitamins or other products of heading 2936 3004 60 – other, containing antimalarial active principles described in Subheading Note 2 to this Chapter 3004 90 – other

This heading covers medicinal products consisting of mixed or unmixed products, provided that they are: (a) packaged in dosage form or in forms such as tablets, ampoules (for example, bidistillated water in ampoules of 1.25 to 10 cm3, used or for the direct treatment of certain diseases, for example, alcoholism, diabetic coma, or as solvents for the preparation of medicinal solutions for injection), capsules, starch capsules, drops or lozenges, drugs in the form of a single-use drug, in the form of a single dose, or in the form of a single-use system, or as a preventive dose.

This heading also covers medicaments in the form of transdermal administration systems, which are usually in the form of self-adhesive patches (generally rectangular or round) and are applied directly to the patient's skin. The active substance is contained in the part of the patch closed by a porous membrane on the side in contact with the skin. The active substance released from the patch is absorbed through the skin by passive molecular diffusion and enters directly into the bloodstream. Such systems should not be confused with the medical adhesive plasters of heading 3005. The heading covers single doses both in bulk packings and in packings for retail sale, etc.; or (b) Put up in packings for retail sale for therapeutic or prophylactic uses. This refers to products (e.g., sodium bicarbonate and tamarind powder) which, because of their packing and in particular the appropriate directions for use attached to them (statement of the disease or condition for which they are to be used, method of use or application, statement of dosage, etc.), are clearly intended for sale directly to users (private persons, hospitals, etc.) for use for the above purposes without repacking. These directions (in any language) may be given on the label, on a leaflet or elsewhere. However, the mere indication of pharmaceutical or other degree of purity is not in itself sufficient to justify classification in this heading. Nevertheless, unmixed products not accompanied by any directions are to be regarded as put up for retail sale for therapeutic or prophylactic uses if they are put up in a form clearly intended for such use. Medicaments consisting of mixed products for therapeutic or prophylactic uses, not put up in measured doses or in packings for retail sale, fall in heading 3003 (see the corresponding Explanatory Note). Under Note 3 to this Chapter, the following are also to be treated as unmixed products: (1) Unmixed products dissolved in water. (2) All goods of Chapter 28 or 29. Such products include colloidal sulphur and stabilised solutions of hydrogen peroxide. (3) Simple vegetable extracts of heading 1302 merely standardised or dissolved in any solvent (see the Explanatory Note to heading 1302). It should, however, be noted that unmixed products of headings 2843 to 2846 and 2852 are never classified in heading 3004, even if they satisfy the requirements of paragraph (a) or (b) above. For example, colloidal silver falls in heading 2843 even if put up in measured doses or packed and presented as a medicament. The heading covers pastilles, tablets, drops, etc., suitable only for medicinal purposes, such as preparations based on sulphur, charcoal, sodium tetraborate, sodium benzoate, potassium chlorate or magnesium oxide. However, goods put up as throat pastilles or cough drops, consisting essentially of sugar (whether or not they also contain other food substances such as gelatin, starch or flour) and flavouring agents (including substances having medicinal properties, such as benzyl alcohol, menthol, eucalyptol and tolu balsam), fall in heading 1704. Throat pastilles or cough drops containing substances having medicinal properties, other than flavouring

aromatic additives are included in this heading when packaged in the form of ozated dosage forms or in packages for retail sale, provided that the content of these substances in each lozenge or drop is sufficient for use for therapeutic or prophylactic purposes. This heading also includes the following products, provided they are manufactured in accordance with (a) or (b) above: (1) Organic surfactants and preparations with active cation (for example, salts of quaternary ammonium base), having antiseptic, disinfectant, bactericidal or germicidal action. (2) Polyvinylpyrrolidone-iodine, which is a product of the reaction of iodine and polyvinylpyrrolidone. (3) Bone graft substitutes made of calcium sulfate for surgical purposes, which are introduced into the cavity of the broken bone with a syringe and spontaneously dissolved and replaced with bone tissue; these products form a crystalline matrix on which new bone can grow as the matrix dissolves. However, this heading does not include bone-reconstructing cements normally containing a hardener (volcanic agent) and an activator used, for example, for attaching prosthetic implants to an existing bone (heading 3006). The provisions of this heading do not apply to foodstuffs or beverages, such as dietary, diabetic or nutritionally fortified foodstuffs, tonic beverages or mineral waters (natural or artificial), which fall in the relevant headings. This is usually the case with dietary supplements containing only nutrients. The main nutrients in foods are proteins, carbohydrates and fats. Vitamins and mineral salts also play a role in nutrition. Similarly, foodstuffs and beverages containing medicinal substances are not included in this heading if these substances are added for the sole purpose of improving the dietary balance, increasing the energy content or nutritional value of the product or improving its taste and aromatic qualities, provided that the product retains its properties as a food or beverage. In addition, products consisting of a mixture of plants or parts of plants, or of plants and parts of plants mixed with other substances, used for the preparation of herbal infusions or herbal “teas” (for example, herbal infusions or herbal “teas” having laxative, cleansing, diuretic or windward properties), and which are said to alleviate malaise or favorably affect general health and well-being, are also excluded from this heading (heading 2106). In addition, this heading does not include food additives containing vitamins or mineral salts which are prepared for the purpose of maintaining health and well-being, but have no indication of their use for the treatment or prevention of any disease. Such products, which are usually manufactured in liquid form but which may also be supplied in powders or tablets, are generally classified in heading 2106 or Chapter 22. However, this heading covers preparations in which a food product or drink serves as a carrier, a supplement or sweetener for medicinal substances (for example, to improve digestion). This heading also does not include: (a) snake or bee venom not supplied as a medicinal product (heading 3001); (b) goods of heading 3002, 3005 or 3006, however packaged; (c) aqueous distillates or aqueous solutions of essential oils and preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties (heading 33); (d) soaps containing medicinal products, however packaged (heading 3401);

(e) insecticides, disinfectants, etc. of heading 3808, not intended for internal or external use as medicinal products; (f) preparations such as tablets, chewing gum or patches (transdermal systems) intended to help smokers quit (heading 2106 or 3824).

Wadding, gauze, bandages and similar articles (e.g., dressing material, adhesive patches, poultices) impregnated or coated with pharmaceutical substances or packaged in moulds or packages for retail sale intended for use in medicine, surgery, dentistry or veterinary medicine: 3005 10 – material dressing adhesive and other products having a sticky layer 3005 90 – other

This heading covers articles such as wadding, gauze, bandages and similar articles, of textile materials, paper, plastics, etc., impregnated or coated with pharmaceutical substances (anti-inflammatory, antiseptic, etc.), for medical, surgical, dental or veterinary purposes. These articles include wadding impregnated with iodine or methyl salicylate, etc., various prepared dressings, prepared poultices (e.g., of mustard or linseed), medicated adhesive plasters, etc. They may be in the piece, in discs or in any other form. Wadding and gauze for dressings (generally of absorbent cotton), bandages, etc., not impregnated or coated with pharmaceutical substances, are also classified in this heading provided they are put up in forms or packings for retail sale directly to private persons, clinics, hospitals, etc., without repacking, and have characteristics (presented in rolls or folded, in protective packings, labelled, etc.) that identify them as intended exclusively for medical, surgical, dental or veterinary use. The heading also includes the following types of dressings: (1) Skin dressings consisting of strips of frozen or lyophilised (freeze-dried) animal skin tissue, generally pigskin, used as temporary biological dressings for direct application to areas of damaged skin, open tissue wounds, surgical infection sites, etc. They come in various sizes, are put up in sterile packings (for retail sale) and are accompanied by instructions for use. (2) Liquid dressings, put up in aerosol form (for retail sale), used to cover wounds with a protective transparent film. Such dressings may contain a sterile solution of plastics (e.g., a modified vinyl copolymer or a methacrylate-based polymer) in a volatile organic solvent (e.g., ethyl acetate) and a propellant, whether or not with added pharmaceutical substances (in particular, antiseptics). The heading excludes bandages, adhesive plasters and the like containing zinc oxide, and plaster-coated bandages, not put up in forms or packings for retail sale for medical, surgical, dental or veterinary use. The heading further excludes:

(a) specially calcified or finely ground plasters and plaster-based formulations for dental purposes (headings 2520 and 3407, respectively); (b) medicinal products in the form of transdermal systems (heading 3004); (c) the goods referred to in note 4 to this chapter (heading 3006); (d) female sanitary pads and tampons, baby trees and diapers and the like articles of heading 9619.

Official text adopted by a Recommendation of the EEC Board

Notes to chapter 30 — Pharmaceutical products 6 items

Notes

Machine translation. The original is the Russian text of the EAEU tariff, and customs goes by it; this translation is for understanding only and has no legal force.

1. This group does not include:

(a) food or beverages (such as dietary, diabetic or nutritionally fortified foods, food additives, tonic beverages and mineral waters), other than nutrient preparations for intravenous administration (Section IV);

(b) products such as tablets, chewing gum or patches (transdermal systems) containing nicotine and intended to contribute to the cessation of tobacco consumption (heading 2404);

(c) specially calcified or finely ground plasters for use in dentistry (heading 2520);

(d) aqueous distillates or aqueous solutions of essential oils intended for medical use (heading 3301);

(e) preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties;

(f) soap or other products of heading 3401 containing medicinal additives;

(g) g gypsum-based products for use in dentistry (heading 3407);

(h) blood albumin not prepared for therapeutic or prophylactic use (heading 3502); or

(ij) diagnostic reagents of heading 3822.

2. For the purposes of heading 3002, the term “immunological products” applies to peptides and proteins (other than those of heading 2937) which are directly involved in the regulation of immunological processes such as monoclonal antibodies (MABs), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFNs), chemokines and certain tumor necrosis factors (TNFs), growth factors (GFs), hematopoietines and colony-stimulating factors (CSFs).

3. In headings 3003 and 3004 and note 4(d) to this chapter it is understood:

(a) unmixed products:

(1) unmixed products dissolved in water;

(2) all goods of Chapter 28 or 29; and

(3) simple plant extracts of heading 1302, only standardized or dissolved in any solvent;

(b) under mixed products:

(1) colloidal solutions and suspensions (except colloidal sulfur);

(2) plant extracts obtained by treatment of mixtures of plant raw materials; and

(3) salts and concentrates obtained by evaporation of natural mineral waters.

4. Heading 3006 covers only the following products, which are to be classified in this and no other heading of the Nomenclature:

(a) sterile surgical ketgut, similar sterile suture materials (including sterile absorbable surgical or dental threads) and sterile adhesive tissues for surgical wound closure;

(b) sterile kelp and sterile tampons of kelp;

(c) sterile resorbable surgical or dental hemostatic agents (hemostatics); sterile surgical or dental adhesive barriers, resorbable or non-absorbable;

(d) contrast preparations for X-ray examinations and diagnostic reagents intended for administration to patients, which are unmixed substances in dosage forms or substances consisting of two or more components mixed for such use;

(e) placebos and sets of impersonal clinical preparations for the conduct of approved clinical trials by simple blind (or double blind) method, packaged in dosage forms, even if they may contain active (active) medicinal substances;

(f) dental cements and other materials for filling teeth; cements for reconstructing bone;

(g) sanitary bags and first aid kits;

(h) chemical contraceptives based on hormones, other compounds of heading 2937 or spermicides;

(ij) preparations in the form of a gel intended for use in medicine or veterinary medicine as a lubricant for body parts in surgical operations or physical investigations or as a binding agent between the body and medical instruments;

(k) unsuitable pharmaceuticals, i.e. pharmaceutical products, which are not suitable for use for their original purpose, for example because they have expired; and

(l) devices identified as devices for stomic use, i.e. colostomy, ileostomy and urostomy bags cut in shape and their sticky plates or front parts.

Subheading notes

English text as published in Annex I to Regulation (EU) 2021/1832 (Combined Nomenclature). The EAEU tariff and the EU nomenclature copy these notes from the same convention. For a Russian declaration the binding version is the Russian one: Annex to Decision No 80 of the EEC Council of 14 September 2021.

1. For the purposes of subheadings 3002 13 and 3002 14, the following are to be treated:

(a) as unmixed products, pure products, whether or not containing impurities;

(b) as products which have been mixed:

(1) the products mentioned in (a) above dissolved in water or in other solvents;

(2) the products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and

(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.

2. Subheadings 3003 60 and 3004 60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients : amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).

EEC classification decisions (6)

Binding in all EAEU member states: if the goods match the description, the decision fixes the code

  • 3004 90 000 2Decision No. 38 of Mar 30, 2021decision text → No. 38, opens in a new tab

    Препарат в форме раствора для внутривенных и внутримышечных инъекций, содержащий в качестве активного действующего вещества депротеинизированный гемодиализат, полученный из крови телят Препарат в форме дентальной адгезивной пасты, содержащий в качестве активных действующих веществ депротеинизированный гемодиализат, полученный из крови телят

  • 3004Decision No. 166 of Dec 8, 2020decision text → No. 166, opens in a new tab

    Препарат для лечения угревой сыпи

  • 3004 90 000Decision No. 63 of Apr 24, 2018decision text → No. 63, opens in a new tab

    Препараты для лечения заболеваний дыхательных путей

  • 3004Decision No. 126 of Sep 26, 2017decision text → No. 126, opens in a new tab

    Противовирусный препарат для лечения ВИЧ-инфицированных пациентов

  • 3004Decision No. 17 of Feb 9, 2016decision text → No. 17, opens in a new tab

    Имплантат для внутрисуставного введения

  • 3004Decision No. 102 of Sep 1, 2015decision text → No. 102, opens in a new tab

    Отдельные водные растворы для гемодиализа

Classification rulings for this code (115)

Machine translation from Russian. The original is the Russian wording of the ruling, and customs goes by it; this translation is for understanding only and has no legal force.

Лекарственный препарат «...» в виде спрея назального (бесцветный прозрачный раствор без запаха), содержащий в 1 мл спрея в качестве действующего вещества ксилометазолина гидрохлорид 1,00 мг, не содержащий йод или соединения йода.

Full description

Применяется при острых респираторных заболеваниях с явлениями ринита (насморка), остром аллергическом рините, поллинозе, синусите, евстахиите, среднем отите (в составе комбинированной терапии для уменьшения отека слизистой оболочки носоглотки), при подготовке пациента к диагностическим манипуляциям в носовых ходах. Расфасован в упаковки для розничной продажи. Форма выпуска: по 15 мл препарата во флаконе, снабженном распылительным устройством и защитной крышкой с инструкцией по применению в картонной пачке.

GRI 1 and 6

The drug "..." in the form of a nasal spray (colorless transparent solution without odor), containing in 1 ml of the spray as the active substance of xylometazoline hydrochloride 0.50 mg, not containing iodine or iodine compounds.

Full description

It is used in acute respiratory diseases with the phenomena of rhinitis (rhinitis), acute allergic rhinitis, pollinosis, sinusitis, Eustachitis, otitis media (as part of combined therapy to reduce edema of the nasopharyngeal mucosa), in preparing the patient for diagnostic manipulations in the nasal passages.

Packaged in packaging for retail sale. Release form: 15 ml of the drug in a bottle equipped with a spraying device and a protective cover with instructions for use in a cardboard pack.

GRI 1 and 6

Лекарственный препарат в виде таблеток (таблетки овальной формы белого или почти белого цвета, не содержащие посторонних включений, на одной стороне имеется риска, другая сторона гладкая), содержащий в одной таблетке в качестве действующего вещества лоратадин 10,0 мг, не содержащий йод и соединения йода.

Full description

Применяется как противоаллергическое средство при сезонном (поллиноз) и круглогодичном аллергическом рините и аллергическом конъюнктивите, при хронической идиопатической крапивнице. Расфасован в упаковки для розничной продажи. Форма выпуска: по 1, 2 или 3 блистера по 7, 10 или 15 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

The drug [name omitted] in the form of capsules (opaque solid gelatin capsules No. 0, consisting of two parts: a blue cap and a white body, with the inscription blue ", filled with white or almost white powder with a weak odor), containing in 1 capsule as active substances: glucosamine sulfate in the form of D-glucosamine potassium chloride sulfate 250.0 mg, chondroitin sodium sulfate 200.0 mg, ibuprofen 100.0 mg, not containing iodine and compounds.

Full description

It is used for osteoarthritis of large joints, osteochondrosis of the spine, accompanied by moderate pain syndrome.

Packaged in packaging for retail sale. Release form: 1 bottle of 30, 60 or 120 capsules with instructions for use in a cardboard pack.

GRI 1 and 6

Лекарственный препарат [наименование опущено] в виде капсул (прозрачные твердые желатиновые капсулы № 00, содержимое капсул – порошок белого или белого с желтоватым оттенком цвета с кристаллическими частицами), содержащий в 1 капсуле в качестве действующих веществ: глюкозамина гидрохлорид 500,0 мг, хондроитина сульфат натрия 400,0 мг, не содержащий йод и соединения йода.

Full description

Применяется при дегенеративно-дистрофических заболеваниях суставов и позвоночника: остеоартроз I – III стадии, остеохондроз. Расфасован в упаковки для розничной продажи. Форма выпуска: по 1 флакону по 30, 60, 100, 120 или 200 капсул с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат [наименование опущено] в виде капель глазных (прозрачный бесцветный раствор), содержащий в 1 мл в качестве действующего вещества тетризолина гидрохлорид 0,5 мг, не содержащий йод и соединения йода.

Full description

Применяется как альфа-адреномиметик для снятия гиперемии (покраснения глаз) и отека конъюнктивы, обусловленных воздействием химических и физических факторов (дым, пыль, ветер, хлорированная вода, свет, контактные линзы), а также возникающих при аллергических реакциях, таких как поллиноз. Расфасован в упаковки для розничной продажи. Форма выпуска: по 10 мл в пластиковом флаконе с капельным устройством системы 3К, обеспечивающим стерильность раствора, и защитным колпачком с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат [наименование опущено] в виде капель глазных (прозрачный раствор желтовато-зеленого цвета), содержащий в 1 мл в качестве действующего вещества бримонидина тартрат 2,00 мг, не содержащий йод и соединения йода.

Full description

Применяется как противоглаукомное средство – альфа2-адреномиметик селективный при открытоугольной глаукоме, офтальмогипертензии (в монотерапии или в комбинации с другими препаратами, снижающими внутриглазное давление). Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 мл в полиэтиленовом флаконе с капельницей-насадкой и навинчивающейся крышкой с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде геля для наружного применения (прозрачный однородный гель от жёлтого до жёлто-оранжевого цвета со слабым запахом), содержащее (на 100 г): активный компонент – настойку гомеопатическую матричную Arnica montana (арника монтана) 7,0 г; вспомогательные вещества – карбомер 0,90 г, натрия гидроксида раствор 10% 1,70 г, этанол (спирт этиловый) 96% 20,0 г, вода очищенная 70,40 г.

Full description

Применяется при ушибах, синяках, мышечной боли вследствие чрезмерной физической нагрузки. Расфасовано в упаковки для розничной продажи. Форма выпуска: по 45 г или 120 г средства в алюминиевой тубе с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде раствора для приема внутрь (прозрачная бесцветная жидкость), содержащее в 1 дозе в качестве активных компонентов: Chamomilla vulgaris (хамомилла вульгарис)

Full description

С9 333,3 мг, Phytolacca decandra (фитолякка декандра) С5 333,3 мг, Rheum (реум) С5 333,3 мг, в качестве вспомогательного компонента воду очищенную до 1 мл, не содержащее йод или соединения йода. Применяется при болезненном прорезывании зубов у грудных детей. Расфасовано в упаковки для розничной продажи. Форма выпуска: по 2 или 6 пакета-саше по 5 спаянных между собой полиэтиленовых контейнеров по 1 дозе (1 мл) раствора в каждом с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде таблеток, покрытых оболочкой (таблетки двояковыпуклой формы, покрытые оболочкой белого цвета, без запаха), содержащее в 1 таблетке в качестве активных компонентов: Aconitum napellus (аконитум напеллюс)

Full description

С3 0,091 мг, Arum triphyllum (арум трифиллум) С3 0,091 мг, Ferrum phosphoricum (феррум фосфорикум) С6 0,091 мг, Calendula officinalis (календула оффициналис) С6 0,091 мг, Spongia tosta (спонгиа тоста) С6 0,091 мг, Belladonna (белладонна) С6 0,091 мг, Mercurius solubilis (меркуриус солюбилис) С6 0,091 мг, Hepar sulfur (гепар сульфур) С6 0,091 мг, Kalium bichromicum (калиум бихромикум) С6 0,091 мг, Populus candicans (популюс кандиканс) С6 0,091 мг, Bryonia (бриония) С3 0,091 мг, не содержащее йод или соединения йода.

Применяется при ларингитах различной этиологии, в том числе потере голоса, хрипоте, усталости голосовых связок. Расфасовано в упаковки для розничной продажи. Форма выпуска: по 3 или 5 блистеров по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде прозрачного сиропа светло-желтого с коричневатым оттенком цвета, с ароматным запахом, в состав которого входят (на 100 г): активные компоненты – Pulsatilla (пульсатилла)

Full description

С6 0,95 г, Rumex crispus (румекс криспус) С6 0,95 г, Bryonia (бриония) С3 0,95 г, Ipeca (ипека) С3 0,95 г, Spongia tosta (спонгия тоста) С3 0,95 г, Sticta pulmonaria (стикта пульмонария) С3 0,95 г, Antimonium tartaricum (антимониум тартарикум) С6 0,95 г, Myocarde (миокардэ) С6 0,95 г, Coccus cacti (коккус какти) С3 0,95 г, Drosera (дрозера) МТ 0,95 г; вспомогательные компоненты – сироп Толу 19,0 г, сироп Полигала 19,0 г, карамель 0,125 г, бензойная кислота 0,085 г, этанол 96% 0,340 г, сироп сахарозы до 100 г, не содержащий йод или соединения йода.

Применяется для симптоматического лечения кашля различной этиологии. Расфасован в упаковки для розничной продажи. Форма выпуска: по 200 мл препарата во флаконе с мерным колпачком и инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (круглые таблетки двояковыпуклой формы белого цвета, с гравировкой SEDATIF P.C. на одной стороне, без запаха или со слабым запахом), содержащий в 1 таблетке в качестве активных компонентов: Aconitum napellus (аконитум напеллюс)

Full description

С6 0,5 мг, Belladonna (беладонна) С6 0,5 мг, Calendula officinalis (календула оффициналис) С6 0,5 мг, Chelidonium majus (хелидониум майюс) С6 0,5мг, Jequirity (еквирити) С6 0,5 мг, Viburnum opulus (вибурнум опулюс) С6 0,5 мг, не содержащий йод или соединения йода. Применяется при тревожных расстройствах, беспокойстве, нарушениях сна. Расфасован в упаковки для розничной продажи. Форма выпуска: по 2 блистера по 20 таблеток либо по 5 блистеров по 18 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде таблеток (таблетки цилиндрические двояковыпуклой формы, белого цвета, без запаха или со слабым запахом), содержащее в 1 таблетке в качестве активных компонентов: Cocculus indicus (коккулюс индикус)

Full description

С4 0,375 мг, Nux vomica (нукс вомика) С4 0,375 мг, Tabacum (табакум) С4 0,375 мг, Petroleum (петролеум) С4 0,375 мг, не содержащее йод или соединения йода. Применяется для профилактики и лечения укачивания в транспорте у взрослых и детей с 3 лет. Расфасовано в упаковки для розничной продажи. Форма выпуска: по 3 блистера по 10 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде капель глазных (прозрачная бесцветная жидкость), содержащий (на 100 г) в качестве активных компонентов: Euphrasia officinalis (эуфразия оффициналис)

Full description

D3 1,0 г, Calendula officinalis (календула оффициналис) D3 0,25 г, Magnesia carbonica (магнезия карбоника) C5 0,25 г, в качестве вспомогательных компонентов: натрия хлорид 0,9 г, вода очищенная – до 100 г, не содержащий йод или соединения йода. Применяется для лечения раздражений и дискомфорта слизистой оболочки глаз, вызванных чрезмерным напряжением зрения, воздействием дыма, пыли, морской или хлорированной воды. Расфасован в упаковки для розничной продажи. Форма выпуска: по 2 или 4 пакета-саше по 5 спаянных между собой полиэтиленовых контейнеров по 0,4 мл препарата в каждом с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде таблеток, покрытых оболочкой (таблетки двояковыпуклой формы, покрытые оболочкой белого цвета, без запаха), содержащее в 1 таблетке в качестве активных компонентов: Allium cepa (аллиум цепа)

Full description

С3 0,333 мг, Belladonna (белладонна) C3 0,333 мг, Sabadilla (сабадилла) С3 0,333 мг, Kalium bichromicum (калиум бихромикум) С3 0,333 мг, Gelsemium (гельземиум) С3 0,333 мг, Pulsatilla (пульсатилла) С3 0,333 мг, не содержащее йод или соединения йода. Применяется при насморке (отек и/или раздражение слизистой носоглотки, сочетающиеся или нет с заложенностью носа, чиханием, ознобом). Расфасовано в упаковки для розничной продажи. Форма выпуска: по 2 блистера по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат таблетки гомеопатические (блистер) 20 х 6 (далее - Препарат) является многокомпонентным гомеопатическим лекарственным препаратом, приготовленным из растительного сырья, действие которого обусловлено компонентами, входящими в его состав.

Full description

Препарат применяется в гинекологической эндокринологии по рекомендации врача в комплексной терапии. Содержание активных компонентов в 1 таблетке составляет: 1) Прутняк обыкновенный (Vitex agnus castus (Agnus castus)) Ø (D1) – 162 мг; 2) Стеблелист василистниковидный (Caulophyllum thalictroides) D4 - 81 мг; 3) Фиалка альпийская (Cyclamen europaeum (Cyclamen)) D4 - 81 мг; 4) Грудошник горький (Strychnos ignatii (Ignatia)) D6 - 81 мг; 5) Касатик разноцветный (Iris versicolor (Iris)) D2 - 162 мг; 6) Тигровая лилия (Lilium lancifolium (Lilium tigrinum))

D3 - 81 мг. Вспомогательные вещества: крахмал картофельный, магния стеарат, лактозы моногидрат. Препарат упакован для розничной продажи в картонную пачку, в которую помещают 6 блистеров по 20 таблеток и инструкцию по медицинскому применению.

GRI 1 and 6

Лекарственный препарат в виде капель для приема внутрь без вкуса (прозрачный или слегка мутный желтовато-коричневый раствор с характерным кисловатым карамелеподобным запахом), содержащий в 100 мл: в качестве действующих веществ - водный субстрат продуктов обмена веществ Escherichia coli DSM 4087 (24,9481 г), водный субстрат продуктов обмена веществ Enterococcus faecalis DSM 4086 (12,4741 г), водный субстрат продуктов обмена веществ Lactobacillus acidophilus DSM 4149 (12,4741 г), водный субстрат продуктов обмена веществ Lactobacillus helveticus DSM 4183 (49,8960 г); в качестве вспомогательных веществ – натрия фосфат гептагидрат, дикалия фосфат, молочная кислота, фосфорная кислота концентрированная, калия сорбат, кислоты лимонной моногидрат.

Full description

Не содержит йод или соединения йода. Применяется в терапевтических или профилактических целях при нарушении физиологической флоры тонкого и толстого кишечника; синдроме недостаточности пищеварения, диспепсии; диарее, метеоризме запоре; гастроэнтерите, колите, синдроме старческого кишечника; расстройствах со стороны желудочно-кишечного тракта, вызванных сменой климата; гипо- и анацидных состояниях; энтерогенных заболеваниях желчного пузыря и печени; аллергических кожных заболеваниях; сальмонеллезе в стадии реконвалесценции.

Расфасован в упаковки для розничной продажи. Форма выпуска: по 100 мл препарата во флаконе из коричневого стекла с закручивающейся пластмассовой крышкой с защитным кольцом и пробкой-капельницей, с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат таблетки гомеопатические (блистер) 20 х 3 (далее - Препарат) является многокомпонентным гомеопатическим лекарственным препаратом, приготовленным из растительного сырья, действие которого обусловлено компонентами, входящими в его состав.

Full description

Препарат применяется в гинекологической эндокринологии по рекомендации врача в комплексной терапии. Содержание активных компонентов в 1 таблетке составляет: 1) Прутняк обыкновенный (Vitex agnus castus (Agnus castus)) Ø (D1) – 162 мг; 2) Стеблелист василистниковидный (Caulophyllum thalictroides) D4 - 81 мг; 3) Фиалка альпийская (Cyclamen europaeum (Cyclamen)) D4 - 81 мг; 4) Грудошник горький (Strychnos ignatii (Ignatia)) D6 - 81 мг; 5) Касатик разноцветный (Iris versicolor (Iris)) D2 - 162 мг; 6) Тигровая лилия (Lilium lancifolium (Lilium tigrinum))

D3 - 81 мг. Вспомогательные вещества: крахмал картофельный, магния стеарат, лактозы моногидрат. Препарат упакован для розничной продажи в картонную пачку, в которую помещают 3 блистера по 20 таблеток и инструкцию по медицинскому применению.

GRI 1 and 6

Лекарственный препарат капли для приема внутрь гомеопатические (флакон) 50 мл х 1 (далее - Препарат) является многокомпонентным гомеопатическим лекарственным препаратом, приготовленным из растительного сырья, действие которого обусловлено компонентами, входящими в его состав.

Full description

Препарат применяется в гинекологической эндокринологии по рекомендации врача в комплексной терапии. Содержание активных компонентов Препарата в расчете на 100 грамм капель составляет: 1) Прутняк обыкновенный (Vitex agnus castus (Agnus castus)) D1 - 20 г; 2) Стеблелист василистниковидный (Caulophyllum thalictroides) D4 - 10 г; 3) Фиалка альпийская (Cyclamen europaeum ( Cyclamen)) D4 - 10 г; 4) Грудошник горький (Strychnos ignatii (Ignatia)) D6 - 10 г; 5) Касатик разноцветный (Iris versicolor (Iris)) D2 - 20 г; 6) Тигровая лилия (Lilium lancifolium (Lilium tigrinum))

D3 - 10 г. Вспомогательные вещества: этанол 47,0 — 53,0 % (об/об). Препарат упакован для розничной продажи во флаконы из темного стекла по 50 мл с дозирующим капельным устройством сверху, с навинчивающейся крышкой и с предохранительным кольцом. Каждый флакон вместе с инструкцией по медицинскому применению помещают в картонную пачку.

GRI 1 and 6

Лекарственный препарат капли для приема внутрь гомеопатические (флакон) 100 мл х 1 (далее - Препарат) является многокомпонентным гомеопатическим лекарственным препаратом, приготовленным из растительного сырья, действие которого обусловлено компонентами, входящими в его состав.

Full description

Препарат применяется в гинекологической эндокринологии по рекомендации врача в комплексной терапии. Содержание активных компонентов Препарата в расчете на 100 грамм капель составляет: 1) Прутняк обыкновенный (Vitex agnus castus (Agnus castus)) D1 - 20 г; 2) Стеблелист василистниковидный (Caulophyllum thalictroides) D4 - 10 г; 3) Фиалка альпийская (Cyclamen europaeum ( Cyclamen)) D4 - 10 г; 4) Грудошник горький (Strychnos ignatii (Ignatia)) D6 - 10 г; 5) Касатик разноцветный (Iris versicolor (Iris)) D2 - 20 г; 6) Тигровая лилия (Lilium lancifolium (Lilium tigrinum))

D3 - 10 г. Вспомогательные вещества: этанол 47,0 — 53,0 % (об/об). Препарат упакован для розничной продажи во флаконы из темного стекла по 100 мл с дозирующим капельным устройством сверху, с навинчивающейся крышкой и с предохранительным кольцом. Каждый флакон вместе с инструкцией по медицинскому применению помещают в картонную пачку.

GRI 1 and 6

Лекарственный препарат в виде крема для наружного применения (однородный крем от светло-желтого с зеленоватым оттенком до желтого с зеленоватым оттенком цвета с запахом диметилсульфоксида), содержащий в 1 г крема в качестве действующих веществ: хондроитина сульфат натрия 50,0 мг и мелоксикам 10,0 мг, не содержащий йод и соединения йода.

Full description

Применяется как регенерации тканей стимулятор + нестероидный противовоспалительный препарат в составе комплексной терапии дегенеративно-дистрофических заболеваний опорно-двигательного аппарата: остеоартроза, остеохондроза позвоночника, иных заболеваний суставов, сопровождающихся болевым синдромом. Расфасован в упаковки для розничной продажи. Форма выпуска: по 10, 20, 25, 30, 50 или 100 г крема в тубе алюминиевой с крышкой из полипропилена с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (таблетки плоскоцилиндрической формы, белого или почти белого цвета, с фаской, возможно образование отдельных темных вкраплений), содержащий в одной таблетке в качестве активных компонентов: Aconitum napellus (Aconitum)

Full description

(Аконитум напеллус) Аконитум)) D3 – 25,0 мг, Gelsemium sempervirens (Gelsemium) (Гельземиум семпервиренс) (Гельземиум)) D3 – 25,0 мг, Cephaelis ipecacuanha (Ipecacuanha) (Цефалис ипекакуана) (Ипекакуана)) D3 – 25,0 мг, Phosphorus (Фосфорус) D5 – 25,0 мг, Bryonia (Бриония) D2 – 25,0 мг, Eupatorium perfoliatum (Эупаториум перфолиатум) D1 – 25,0 мг; в качестве вспомогательных компонентов: лактозы моногидрат, крахмал пшеничный, магния стеарат, не содержащий йод или соединения йода. Применяется для профилактики и лечения гриппа и других острых респираторных вирусных инфекций.

Оказывает самостоятельное терапевтическое и профилактическое действие без использования других лекарственных средств. Расфасован в упаковки для розничной продажи. Форма выпуска: по 2 или 3 блистера по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат в виде раствора для приема внутрь (прозрачная жидкость светло-коричневого цвета с запахом вишни, допускается наличие легкой опалесценции, содержащий в 100 мл препарата в качестве активного компонента: плюща обыкновенного листьев экстракт сухой, экстрагент этанол 30% (5 – 7,5 : 1) – 700,00 мг; в качестве вспомогательных веществ: вода очищенная, калия сорбат, лимонная кислота безводная, сорбитол жидкий кристаллизующийся, камедь ксантановая, ароматизатор вишневый, не содержащий йод или соединения йода.

Full description

Применяется в качестве отхаркивающего средства в терапии острых и хронических заболеваний дыхательных путей, сопровождающихся кашлем с трудноотделяемой мокротой. Расфасован в упаковки для розничной продажи. Форма выпуска: по 100 мл или 200 мл во флаконе темного стекла с пробкой-дозатором, навинчиваемой крышкой и мерным колпачком с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (плоскоцилиндрической формы таблетки от светло-серого до серого цвета, с фаской, допускается наличие вкраплений), содержащий в одной таблетке в качестве активных компонентов: Cimicifuga racemosa (Cimicifuga)

Full description

(цимицифуга рацемоза) (цимицифуга)) D2 - 25,0 мг, Sepia officinalis (Sepia) (сепия оффициналис) (сепия)) D2 - 25,0 мг, Strychnos ignatii (Ignatia) (стрихнос игнации) (игнация)) D3 – 25,0 мг, Sanguinaria canadensis (Sanguinaria) (сангвинария канаденсис) (сангвинария)) D6 – 25,0 мг; в качестве вспомогательных компонентов: лактозы моногидрат, крахмал пшеничный, магния стеарат, не содержащий йод или соединения йода. Применяется для лечения расстройств климактерического периода (климактерический синдром, сопровождающийся приливами жара, усиленным потоотделением, сердцебиением, головокружением, зудом, нервным напряжением, нарушением сна).

Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 блистеров по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (плоскоцилиндрической формы таблетки белого или почти белого цвета с фаской, без запаха или с характерным запахом, возможно наличие одиночных вкраплений темно-серого цвета), содержащий в одной таблетке в качестве активных компонентов:Atropinum sulfuricum (атропинум сульфурикум)

Full description

D5 – 12,50 мг, Hepar sulfuris (Hepar sulfuris calcareum) (гепар сульфурис (гепар сульфурис калькареум)) D3 – 10,00 мг, Kalium bichromicum (калиум бихромикум) D4 – 50,00 мг, Acidum silicicum (Silicea) (ацидум силицикум (силицеа)) D2 – 5,00 мг, Hydrargyrum biiodatum (Mercurius bijodatus) (гидраргиум бииодатум (меркуриус бийодатус)) D8 – 25,0 мг; в качестве вспомогательных компонентов: лактозы моногидрат, сахароза, магния стеарат, не содержащий йод или соединения йода. Применяется для лечения острых и хронических тонзиллитов, острой катаральной, лакунарной или фолликулярной ангины, ускорения заживления слизистой оболочки глотки после удаления миндалин (в составе комплексной терапии).

Расфасован в упаковки для розничной продажи. Форма выпуска: по 3 блистера по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Medication in the form of an oral solution (transparent light yellow liquid with strawberry smell), containing 15.00 mg hydrochloride in 5 ml of the solution as the active ingredient of ambroxol (in 1 ml of solution - ambroxol hydrochloride 3.00 mg), not containing iodine and iodine compounds.

Full description

It is used in adults and children older than 2 years with acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum (acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficult sputum discharge, bronchiectasis).

Packaged in packaging for retail sale. Release form: 120 ml of the drug in a vial equipped with a polypropylene measuring cap, with a leaflet insert in a cardboard pack.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде спрея назального (прозрачная или слабо опалесцирующая, бесцветная или слегка светло-желтая жидкость без запаха), содержащий в 100 г спрея в качестве активных компонентов: Euphorbium (Эуфорбиум)

Full description

D4 1,0 г, Pulsatilla pratensis (Пульсатилла пратенсис) D2 1,0 г, Luffa operculata (Люффа оперкулята) D2 1,0 г, Hydrargyrum biiodatum (Гидраргирум бийодатум) D8 1,0 г, Mucosa nasalis suis (Мукоза назалис суис) D8 1,0 г, Hepar sulfuris (Гепар сульфурис) D10 1,0 г, Argentum nitricum (Аргентум нитрикум) D10 1,0 г, Sinusitis-Nosode (Синуситис-Нозоде) D13 1,0 г; в качестве вспомогательных веществ: бензалкония хлорида раствор, натрия хлорид, натрия дигидрофосфата дигидрат, натрия гидрофосфата дигидрат, вода очищенная. Применяется при лечении ринитов различной этиологии и хронических синуситов.

Расфасован в упаковки для розничной продажи. Форма выпуска: по 20 мл во флаконе коричневого стекла с дозатором-распылителем и защитным колпачком, с инструкцией по применению в картонной пачке.

GRI 1 and 6

Homeopathic medicinal product in the form of tablets for resorption (tablets of white color of flat-cylindrical form, chamfered containing in one tablet as active components: Belladonna (belladonna)

Full description

D6 15 mg, Chamomilla recutita (chamomilla) D6 15 mg, Ferrum phosphoricum (ferrum phosphoricum) D6 15 mg, Hepar sulfuris (sulfuris hepar) D12 15 mg, Pulsatilla pratensis (pulsatilla pratensis) D6 15 mg; as supporting components: cellulose microcrystalline, lactose monohydrate, talc Magnesium stearate, No iodine or iodine compounds. It is used to treat painful symptoms of teething in children, such as: painful sensitivity, swelling and inflammation of the gums; anxiety and irritability; fever; otalgia; diarrhea.

Packaged in packaging for retail sale. Release form: 150 tablets in a bottle of brown glass with a plastic cover, with instructions for use in a cardboard pack.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (таблетки плоскоцилиндрической формы белого или почти белого цвета с фаской, допускается наличие отдельных вкраплений), содержащий в одной таблетке в качестве активных компонентов: Cinnabaris (Циннабарис)

Full description

D3 – 25,0 мг, Hydrastis (Гидрастис) D3 – 25,0 мг, Kalium bichromicum (Калиум бихромикум) D3 – 25,0 мг, Echinacea (Эхинацея) D1 – 25,0 мг; в качестве вспомогательных компонентов: лактозы моногидрат, крахмал пшеничный, магния стеарат, не содержащий йод или соединения йода. Применяется для лечения острых и хронических синуситов (воспаление придаточных пазух носа: гайморита, фронтита и т.д.) в комплексной терапии. Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 блистеров по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

A drug in the form of an oral solution (a transparent light yellow liquid with a raspberry smell), containing 30.00 mg hydrochloride in 5 ml of the solution as the active ingredient of ambroxol (in 1 ml of a solution - ambroxol hydrochloride 6.00 mg), not containing iodine and iodine compounds.

Full description

It is used for acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum (acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficult sputum discharge, bronchiectasis).

Packaged in packaging for retail sale. Release form: 120 ml of the drug in a bottle with a screw cover, equipped with a measuring cup, with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of a solution for oral administration (transparent liquid of light yellow color with a raspberry smell), containing in 5 ml of a solution as the active ingredient of ambroxol hydrochloride 30.00 mg (in 1 ml of a solution - ambroxol hydrochloride 6.00 mg), not containing iodine and iodine compounds.

Full description

It is used in adults and children over 6 years of age for the treatment of acute and exacerbated chronic diseases of the bronchi and lungs, accompanied by the formation of pathologically altered bronchial secretion and difficult excretion of sputum (acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty of sputum discharge, bronchectatic disease).

Packaged in packaging for retail sale. Release form: 120 ml of the drug in a bottle with a screw cover, equipped with a measuring cup, with instructions for use in a cardboard pack.

GRI 1 and 6

Лекарственный препарат [наименование опущено] в виде сиропа (вязкая жидкость светло-желтого цвета с характерным запахом), содержащий в 100,0 г сиропа в качестве действующего вещества экстракт корня алтея лекарственного 35,9 г, в качестве вспомогательных веществ: сахароза 63,865 г, калия сорбат 0,135 г, лимонной кислоты моногидрат 0,1 г, не содержащий йод и соединения йода.

Full description

Применяется как отхаркивающее средство при заболеваниях дыхательных путей, сопровождающихся кашлем с трудноотделяемой мокротой (трахеит, бронхит, трахеобронхит). Расфасован в упаковки для розничной продажи. Форма выпуска: по 150 мл препарата во флаконе с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат [наименование опущено] в виде капель глазных (прозрачный бесцветный или почти бесцветный, слегка вязкий раствор), содержащий в 1 мл в качестве действующего вещества дорзоламида гидрохлорид 22,3 мг (в пересчете на дорзоламид 20,0 мг), не содержащий йод и соединения йода.

Full description

Применяется как противоглаукомное средство – карбоангидразы ингибитор для лечения повышенного внутриглазного давления (ВГД). Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 мл во флаконе со встроенной капельницей и навинчивающейся крышкой с индикатором вскрытия с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат в виде капель глазных (прозрачный раствор зеленовато-желтого цвета), содержащий в 1 мл в качестве действующего вещества моксифлоксацина гидрохлорид 5,45 мг (в пересчете на моксифлоксацин 5,0 мг), не содержащий йод и соединения йода.

Full description

Применяется как противомикробное средство – фторхинолон при бактериальном конъюнктивите, вызванном чувствительными к моксифлоксацину микроорганизмами. Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 мл в полимерном флаконе-капельнице с винтовой горловиной, укупоренном пробкой капельницей и навинчиваемой крышкой с кольцом первого вскрытия с инструкцией по применению в картонной пачке.

GRI 1 and 6

Drug in the form of eye drops (transparent colorless or almost colorless, slightly viscous solution), containing in 1 ml as active ingredients dorzolamide hydrochloride 22.25 mg (in terms of dorzolamide 20.0 mg) and timolol maleate 6.84 mg (in terms of timolol 5.0 mg), not containing iodine and iodine compounds.

Full description

It is used as a combined antiglaucoma drug (carbonic anhydrase inhibitor + β-blocker) for the treatment of increased intraocular pressure in open-angle glaucoma and pseudoexfoliative glaucoma with insufficient effectiveness of monotherapy or ophthalmohypertension with insufficient response to treatment with beta-blockers.

Packaged in packaging for retail sale. Release form: 5 ml in a bottle of a sealed dropper and a screw lid with an opening indicator with instructions for use in a cardboard pack.

GRI 1 and 6

The drug in the form of tablets coated with a film coating (oval biconvex tablets coated with a film coating, blue, on one side of the tablet engraved ", on the fracture of the tablet has a white nucleus), containing in one tablet as an active substance naproxen sodium 275.0 mg, not containing iodine and iodine compounds.

Full description

It is used as a non-steroidal anti-inflammatory drug for diseases of the musculoskeletal system, for pain syndrome of weak or moderate severity, as well as in the complex therapy of infectious and inflammatory diseases of the ear, throat, nose with severe pain syndrome.

Packaged in packaging for retail sale. Release form: 1 or 2 blisters of 12 tablets with a leaflet in a cardboard pack.

GRI 1 and 6

Лекарственный препарат в виде спрея назального (прозрачный бесцветный раствор), содержащий в 1 мл: в качестве действующих веществ - ксилометазолина гидрохлорид 0,5 мг и натрия гиалуронат 0,1 мг; в качестве вспомогательных веществ – морская вода очищенная, калия дигидрофосфат, вода очищенная, не содержащий йод или соединения йода.

Full description

Применяется при острых респираторных заболеваниях с явлениями ринита (насморка), остром аллергическом рините, поллинозе, синусите, евстахиите, среднем отите (в составе комбинированной терапии для уменьшения отека слизистой оболочки носоглотки), при подготовке пациента к диагностическим манипуляциям в носовых ходах. Расфасован в упаковки для розничной продажи. Форма выпуска: по 15 мл препарата во флаконе, снабженном распылительным устройством и защитной крышкой с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат в виде спрея назального (прозрачный бесцветный раствор), содержащий в 1 мл: в качестве действующих веществ - ксилометазолина гидрохлорид 1,0 мг и натрия гиалуронат 0,1 мг; в качестве вспомогательных веществ – морская вода очищенная, калия дигидрофосфат, вода очищенная, не содержащий йод или соединения йода.

Full description

Применяется при острых респираторных заболеваниях с явлениями ринита (насморка), остром аллергическом рините, поллинозе, синусите, евстахиите, среднем отите (в составе комбинированной терапии для уменьшения отека слизистой оболочки носоглотки), при подготовке пациента к диагностическим манипуляциям в носовых ходах. Расфасован в упаковки для розничной продажи. Форма выпуска: по 15 мл препарата во флаконе, снабженном распылительным устройством и защитной крышкой с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат в виде капсул (твердые желатиновые капсулы, корпус – желтого цвета, крышечка – зеленого, содержимое капсул – частично спрессованный порошок светло-желтого цвета), содержащий в одной капсуле в качестве действующих веществ: гинкго двулопастного листьев экстракт сухой стандартизированный (EGb 761®) с содержанием суммы флавонолгликозидов 24,0% и суммы терпеновых лактонов 6,0% 14,0 мг, гептаминола гидрохлорид 300,0 мг, троксерутин 300,0 мг, не содержащий йод и соединения йода.

Full description

Применяется как ангиопротекторное средство при симптоматической терапии проявлений хронической лимфовенозной недостаточности, таких как тяжесть в ногах, боль в ногах, парестезия, остром геморрое. Расфасован в упаковки для розничной продажи. Форма выпуска: по 3 блистера по 10 капсул с инструкцией по применению в картонной пачке.

GRI 1 and 6

Лекарственный препарат в виде крема для наружного применения (однородный крем белого цвета без запаха), содержащий в 1 г крема в качестве действующего вещества метронидазол 10,00 мг, не содержащий йод и соединения йода.

Full description

Применяется как противомикробное и противопротозойное средство для лечения розацеа и акне. Расфасован в упаковки для розничной продажи. Форма выпуска – по 1 алюминиевой тубе по 25 г с инструкцией по применению в картонной пачке.

GRI 1 and 6

A drug in the form of a lyophilized powder for the preparation of a solution for intravenous and intramuscular administration (lyophilized powder of white or almost white color), containing glutathione 0.6 g in one bottle as an active substance, without iodine and iodine compounds.

Full description

It is used as a detoxification agent in the complex therapy of liver diseases, such as acute and chronic hepatitis of various etiology (viral, alcoholic, toxic), alcoholic cirrhosis, hepatic steatosis, liver fibrosis.

Packaged in packaging for retail sale. Release form: 0.6 g of the drug in a bottle of colorless glass with a capacity of 5.0 ml, 5 bottles in a plastic pallet with instructions for use in a cardboard pack.

GRI 1 and 6

Drug "..." in the form of drops for oral administration, containing in 100 ml as active ingredients of iberica bitter whole fresh plant extract liquid 15.0 ml, dry medicinal roots extract liquid 10.0 ml, chamomiles of pharmacy flowers dry extract liquid 20.0 ml, cumin of ordinary fruits dry extract liquid 10.0 ml, milk thistle spotted fruit dry extract liquid 10.0 ml, Melissa medicinal leaves dry extract liquid 10.0 ml, peppermint leaves dry extract liquid 5.0 ml, May grass celandine dry extract liquid 10.0 ml, Licorice bare roots dry extract liquid 10.0 ml, not containing iodine and iodine compounds, is used to treat functional disorders of the gastrointestinal tract, packaged in packaging for retail sale.

Full description

Release form - 20, 50 or 100 ml in a bottle of dark glass with a dropper with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of an ointment for rectal and external use (homogeneous ointment from white to white with a yellowish tint, not containing foreign inclusions), containing 1 g as an active ingredient: benzocaine 200 mg (20%), not containing iodine or iodine compounds.

Full description

It is used as a local pain reliever for hemorrhoids, cracks of the anus, after proctological operations, during diagnostic manipulations.

Packaged in packaging for retail sale. Release form - 1 tube of 25 g or 28.4 g of the drug with a polyethylene applicator and instructions for use in a cardboard pack.

GRI 1, 3(b) and 6

The drug in the form of a syrup (a mucous solution of a slightly yellow color with a sweetish smell and taste), containing in 100.0 g of syrup althea root extract (Extractum Althaea radix) - 35.9 g, sucrose - 63.865 g, potassium sorbate - 0.135 g, citric acid monohydrate - 0.1 g, without iodine and iodine compounds.

Full description

Pharmacological property of the drug: as an expectorant, enveloping, softening and anti-inflammatory agent for respiratory tract diseases (tracheitis, bronchitis, bronchial asthma).

Packaged in packaging for retail sale. Release form: 150 ml of the drug in a brown pet bottle and a leaflet insert, placed in a folding cardboard box.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (круглые таблетки плоскоцилиндрической формы с фаской, от белого до желто-белого цвета, без запаха или со слабым сладковатым запахом), содержащий в каждой таблетке в качестве активных компонентов: Anamirta cocculus (Анамирта коккулюс)

Full description

D4 210 мг, Conium maculatum (Кониум макулятум) D3 30 мг, Ambra grisea (Амбра гризея) D6 30 мг, Petroleum rectificatum (Петролеум ректификатум) D8 30 мг; в качестве вспомогательных веществ: магния стеарат, лактозы моногидрат. Не содержит йод или соединения йода. Применяется для профилактики и лечения головокружений различного происхождения, в том числе головокружения, связанные с укачиванием в транспорте. Расфасован в упаковки для розничной продажи. Форма выпуска: по 50 таблеток в белом пенале из полипропилена с крышкой из полипропилена, с инструкцией по применению в картонной пачке.

GRI 1 and 6

A drug in the form of tablets coated with a film coating (round, biconvex tablets coated with a film shell of brown color), containing in 1 tablet as an active substance: the anchors of the herbs, a dry extract of 250.0 mg (the ratio of raw materials and extract (35 - 45) : 1)

Full description

(the content of the sum of furostanol saponins in terms of protodioscin - at least 112.5 mg), without iodine or iodine compounds. It is used in complex treatment: erectile dysfunction, including accompanied by reduced libido; infertility in men caused by oligoastenoteratozoospermia, surgical intervention for varicocele, immunological infertility; dyslipidemia to reduce the level of total cholesterol.

Packaged in packaging for retail sale. The form of release - 18 blisters of 10 tablets with a leaflet in a cardboard pack.

GRI 1 and 6

Medication in the form of capsules (solid gelatin capsules No. 0 of light brown color, the contents of the capsule are a powdery mass from light yellow to yellow-brown with agglomerates), containing in 1 capsule as an active substance: milk thistle fruit dry extract - from 163.6 mg to 225.0 mg (equivalent to 90.0 mg silymarin), not containing iodine or iodine compounds.

Full description

It is used in adults and children over 12 years old as part of the complex therapy of toxic liver damage, conditions after acute hepatitis, chronic hepatitis of nonviral etiology, liver steatosis, liver cirrhosis, prevention of liver lesions with prolonged medication, alcohol, chronic intoxication (including occupational).

Packaged in packaging for retail sale. The form of release - 5 blisters of 6 capsules with a leaflet in a cardboard pack.

GRI 1 and 6

A drug in the form of tablets coated with a film coating (round biconvex tablets coated with a film coating, green in color, on a cross section of almost white color), containing in 1 tablet as active substances: metamizole sodium monohydrate 500.0 mg and triacetonamine-4-toluene sulfonate 20.0 mg, without iodine or iodine compounds.

Full description

It is used as an analgesic for short symptomatic treatment from mild to moderately severe pain in the following conditions: headache, toothache and dental procedures, myalgia, neuralgia, joint pain (arthralgia).

Packaged in packaging for retail sale. Release form - 2 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of tablets coated with a shell (tablets coated with a shell, biconvex shape with an outer layer of brown color and an inner layer of white color, on a transverse section, a nucleus from brownish-yellow to light brown), containing in 1 tablet as an active substance: milk thistle of spotted fruits dry extract - from 44.19 to 56.68 mg (equivalent to 35 mg of silymarin), without iodine or iodine compounds.

Full description

It is used in adults and children over 12 years old as a symptomatic agent in the complex treatment of toxic liver lesions caused by alcohol, prolonged use of drugs, chronic intoxication (including occupational), chronic inflammatory liver diseases (chronic hepatitis nonviral etiology), cirrhosis of the liver.

Packaged in packaging for retail sale. Release form - 18 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of tablets coated with a film coating (round biconvex tablets coated with a film coating, green in color, on a cross section of almost white color), containing in 1 tablet as active substances: metamizole sodium monohydrate 500.0 mg and triacetonamine-4-toluene sulfonate 20.0 mg, without iodine or iodine compounds.

Full description

It is used as an analgesic for short symptomatic treatment from mild to moderately severe pain in the following conditions: headache, toothache and dental procedures, myalgia, neuralgia, joint pain (arthralgia).

Packaged in packaging for retail sale. Release form - 10 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Goods in the form of a disposable pre-filled syringe without a needle, containing a solution for intraarticular injections (transparent, viscous, non-toxic, sterile and apyrogenic solution, without odor), which includes: the active component - sodium hyaluronate (hyaluronic acid) 10 mg / ml (corresposes to a concentration of 1%); auxiliary substances - sodium chloride, sodium phosphate bisphate (heptahydrate), sodium phosphate single-sphate (substituted water), and sylated water.

Full description

It is intended for injection into the knee joint as a lubricating and chondroprotective component for the formation of a softening pad inside the joint in the event of a decrease in the viscosity of the synovial fluid due to degenerative disease. It is used: to increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints; to treat / eliminate the inflammatory reaction; to rehabilitate after arthroscopy; to protect the tissues of the knee joint of light and moderate severity; to treat patients who have increased physical activity and regularly load the affected joint.

Packaged in packaging for retail sale. Release form - 2.5 ml of the drug in a disposable syringe without a needle with instructions for use and stickers for the patient (3 pcs) in a cardboard pack.

GRI 1 and 6

A drug in the form of an ointment for local and external use (homogeneous ointment from light yellow to yellow with a characteristic odor), containing 45 g of ointment as an active ingredient: Pomorian lake uterine lye (stabilized lye) 5.40 g (in 100 g of ointment - 12.00 g)), not containing iodine or iodine compounds.

Full description

It is used in the complex treatment of purulent wounds of various origin: infected, surgical superficial purulent processes, including pararectal and post-injection abscesses, trophic ulcers, post-traumatic and atherosclerotic wounds, drug maceration of the skin, skin expressions in Burger's disease, varicose ulcers, cervical erosion, cracks of the breast nipple.

Packaged in packaging for retail sale. Release form - 45 g of the drug in an aluminum tube with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of capsules (smooth, shiny, opaque, white gelatin capsules No. 0 containing a light brown powder with a characteristic yeast smell), containing in one capsule: as an active ingredient - Saccharomyces boulardii CNCM I-745 lyophilisate 250.0 mg; as auxiliary substances - lactose monohydrate, titanium dioxide.

Full description

It does not contain iodine or iodine compounds. It is used to treat and prevent diarrhea of any etiology in adults and children from 1 year old, including intestinal dysbiosis; acute infectious, viral or bacterial diarrhea; diarrhea caused by taking antibiotics; irritable bowel syndrome, enterocolitis, etc.

Packaged in packaging for retail sale. Release form: 10, 20, 30 or 50 capsules in a bottle or 5 blisters of 6 capsules with instructions for use in a cardboard pack.

GRI 1 and 6

Goods in the form of a disposable pre-filled syringe without a needle containing a solution for intraarticular injections (transparent, viscous, non-toxic, sterile and apyrogenic solution, odorless), which includes: the active component - sodium hyaluronate (hyaluronic acid) 20 mg / ml (corresposes to a concentration of 2.0%); auxiliary substances - sodium chloride, sodium phosphate single substituted (dihydrate), sodium phosphate bisphate (substituted), and water heptate.

Full description

It is intended for injection into the knee joint as a lubricating and chondroprotective component for the formation of a softening pad inside the joint in the event of a decrease in the viscosity of the synovial fluid due to degenerative disease. It is used: to increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints; to treat / eliminate the inflammatory reaction; to rehabilitate after arthroscopy; to protect the tissues of the knee joint of light and moderate severity; to treat patients who have increased physical activity and regularly load the affected joint.

Packaged in packaging for retail sale. Release form - 3.0 ml of the drug in a disposable syringe without a needle with instructions for use and stickers for the patient (3 pcs) in a cardboard pack.

GRI 1 and 6

Medication in the form of tablets coated with a shell (tablets coated with a shell, biconvex shape with an outer layer of brown color and an inner layer of white color, on a transverse section, a nucleus from brownish-yellow to light brown), containing in 1 tablet as an active substance: milk thistle of spotted fruits dry extract - from 44.19 to 56.68 mg (equivalent to 35 mg of silymarin), without iodine or iodine compounds.

Full description

It is used in adults and children over 12 years old as a symptomatic agent in the complex treatment of toxic liver lesions caused by alcohol, prolonged use of drugs, chronic intoxication (including occupational), chronic inflammatory liver diseases (chronic hepatitis nonviral etiology), cirrhosis of the liver.

Packaged in packaging for retail sale. Release form - 8 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of tablets (round, flat tablets with a chamfer and risk on the one hand, white or white with a gray hue of color, odorless), containing in 1 tablet as an active ingredient: ketotifen hydrofumarate 1.38 mg (corresponding to 1 mg of ketotifen), not containing iodine or iodine compounds.

Full description

It is used as an anti-allergic agent for atopic bronchial asthma (as part of complex therapy), allergic rhinitis, conjunctivitis.

Packaged in packaging for retail sale. Release form - 3 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of a syrup (transparent viscous liquid from colorless to light yellow color with a specific smell of strawberries), containing 5 ml of syrup as the active ingredient: ketotifen hydrofumarate 1.38 mg (corresponding to 1 mg of ketotifen), not containing iodine or iodine compounds.

Full description

It is used as an anti-allergic agent for atopic bronchial asthma (as part of complex therapy), allergic rhinitis, conjunctivitis.

Packaged in packaging for retail sale. Release form - 100 ml of the drug in a bottle of dark glass with a measuring spoon or measuring cup and instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of a gel for external use (homogeneous yellow gel), containing 40 g of gel as the active ingredient: troxerutin 0,800 g, not containing iodine or iodine compounds.

Full description

It is used as an angioprotective agent for chronic venous insufficiency, varicose veins, superficial thrombophlebitis, periflebitis and phlebothrombosis, post-traumatic edema of soft tissues, hematoma, post-thrombotic syndrome.

Packaged in packaging for retail sale. Release form - 40 g of gel in an aluminum tube with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of rectal suppositories (suppositories of a torpedo-shaped form with a smooth surface from white to light yellow, odorless), containing in 1 suppository as an active substance: indomethacin 0.05 g, not containing iodine or iodine compounds.

Full description

It is used for acute and chronic pain in inflammatory and degenerative diseases of the musculoskeletal system, rheumatic lesions of soft tissues, discopathy, neuritis, plexitis, radiculoneuritis, dysmenorrhea.

Packaged in packaging for retail sale. Release form - 6 suppositories in a contour cell package with instructions for use in a cardboard pack.

A drug in the form of intestinal tablets coated with a film coat (round, biconvex tablets of orange-brown color, a view on the fracture - from white to light yellow), containing in 1 tablet as an active substance: indomethacin 25.00 mg, not containing iodine or iodine compounds.

Full description

It is used for acute and chronic pain in inflammatory diseases of the musculoskeletal system, diseases of periarticular tissues, injuries in athletes, discopathy, neuritis, plexitis, radiculoneuritis, dysmenorrhea.

Packaged in packaging for retail sale. Release form - 1 blister of 30 tablets with instructions for use in a cardboard pack or 45 blisters of 30 tablets with instructions for use in a cardboard box (for hospitals).

GRI 1 and 6

A drug in the form of an oral solution (colorless or yellowish liquid with an orange smell), containing 1.00 g of citrulline malate as the active ingredient in one bag, without iodine or iodine compounds.

Full description

It is used in the symptomatic treatment of functional asthenia (asthenic syndrome, fatigue, increased fatigue, during recovery after a disease), contributes to liver detoxification.

Packaged in packaging for retail sale. Release form: 18 bags of 10 ml solution with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of capsules (solid cylindrical gelatin capsules, a case of pink-brown color, a lid of brown color (capsule size No. 0), the contents of the capsules: a powdery mass from light yellow to yellow-brown with agglomerates, with a weak characteristic odor), containing in 1 capsule as an active substance: milk thistle of spotted fruit dry extract - from 200.0 mg to 275.0 mg (equivalent to 110.0 mg silymarin), without iodine compounds.

Full description

It is used in adults and children over 12 years old as a symptomatic agent in the complex treatment of toxic liver lesions caused by alcohol, prolonged use of drugs, chronic intoxication (including occupational), chronic inflammatory liver diseases (chronic hepatitis nonviral etiology), cirrhosis of the liver.

Packaged in packaging for retail sale. The form of release - 5 blisters of 6 capsules with a leaflet in a cardboard pack.

GRI 1 and 6

Drug in the form of an ointment for external use (yellow homogeneous ointment with a specific smell), containing 100 g of ointment as an active substance: indomethacin 10.0 g, not containing iodine or iodine compounds.

Full description

It is used for back pain in inflammatory and degenerative diseases of the spine, joint pain in osteoarthritis, muscle pain, inflammation and swelling of soft tissues and joints due to injuries and rheumatic diseases, inflammatory diseases of the musculoskeletal system.

Packaged in packaging for retail sale. Release form - 40 g of ointment in an aluminum tube with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of tablets (round biconvex tablets with risk, light pink color with a mint smell), containing in 1 tablet as an active ingredient: molsidomin 2.00 mg, not containing iodine or iodine compounds.

Full description

It is used for the prevention and long-term treatment of stable angina pectoris in adult patients in case of insufficient effectiveness, contraindications to the use or intolerance to other antianginal drugs, as well as in older patients.

Packaged in packaging for retail sale. Release form - 3 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of rectal suppositories (suppositories of a torpedo-shaped form with a smooth surface from white to light yellow, odorless), containing in 1 suppository as an active substance: indomethacin 0.10 g, not containing iodine or iodine compounds.

Full description

It is used for acute and chronic pain in inflammatory and degenerative diseases of the musculoskeletal system, rheumatic lesions of soft tissues, discopathy, neuritis, plexitis, radiculoneuritis, dysmenorrhea.

Packaged in packaging for retail sale. Release form - 6 suppositories in a contour cell package with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of capsules (solid gelatin capsules No. 1 of yellow color, the contents of capsules - granules or a compressed mass taking the form of a capsule, from light yellow to dark yellow color), containing in 1 capsule as the active ingredient: troxerutin 300.0 mg, not containing iodine or iodine compounds.

Full description

It is used as a venotonic and venoprotective agent for chronic venous insufficiency, postthrombotic syndrome, trophic disorders in varicose veins and trophic ulcers, as an auxiliary treatment after sclerotherapy of veins and removal of varicose nodes, hemorrhoids (pain, exudation, itching and bleeding, as an auxiliary treatment for retinopathy in patients with diabetes, arterial hypertension and atherosclerosis).

Packaged in packaging for retail sale. Release form - 5 blisters of 10 capsules with instructions for use in a cardboard pack.

GRI 1 and 6

Goods in the form of a disposable pre-filled syringe without a needle containing a solution for intraarticular injections (transparent, viscous, non-toxic, sterile and apyrogenic solution, odorless), which includes: the active component - sodium hyaluronate (hyaluronic acid) 15 mg / ml (corresposes to a concentration of 1.5%); auxiliary substances - sodium chloride, sodium phosphate single substituted (dihydrate), sodium phosphate bisphate (substituted water), and heptate.

Full description

It is intended for injection into the knee joint as a lubricating and chondroprotective component for the formation of a softening pad inside the joint in the event of a decrease in the viscosity of the synovial fluid due to degenerative disease. It is used: to increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints; to treat / eliminate the inflammatory reaction; to rehabilitate after arthroscopy; to protect the tissues of the knee joint of light and moderate severity; to treat patients who have increased physical activity and regularly load the affected joint.

Packaged in packaging for retail sale. Release form - 2.5 ml of the drug in a disposable syringe without a needle with instructions for use and stickers for the patient (3 pcs) in a cardboard pack.

GRI 1 and 6

A drug in the form of tablets coated with a film coating (round, biconvex tablets coated with a film shell of brown color), containing in 1 tablet as an active substance: the anchors of the herbs, a dry extract of 250.0 mg (the ratio of raw materials and extract (35 - 45) : 1)

Full description

(the content of the sum of furostanol saponins in terms of protodioscin - at least 112.5 mg), without iodine or iodine compounds. It is used in complex treatment: erectile dysfunction, including accompanied by reduced libido; infertility in men caused by oligoastenoteratozoospermia, surgical intervention for varicocele, immunological infertility; dyslipidemia to reduce the level of total cholesterol.

Packaged in packaging for retail sale. The form of release - 6 blisters of 10 tablets with a leaflet in a cardboard pack.

GRI 1 and 6

Drug in the form of tablets (round biconvex tablets from white to almost white), containing in 1 tablet as an active ingredient: cinnarizin 25.00 mg, not containing iodine or iodine compounds.

Full description

It is used in adults - for maintenance therapy: with symptoms of Meniere's disease of labyrinth origin (including vertigo, nausea, vomiting, tinnitus and nystagmus), with symptoms of cerebrovascular origin (including vertigo, tinnitus, headache, irritability, isolation, impaired memory and concentration of attention), with symptoms of peripheral circulation disorders; for the prevention of kinetosis ("road sickness" - sea and air sickness), migraine attacks; in children from 5 years for the prevention of kinetosis.

Packaged in packaging for retail sale. The form of release - 1 blister of 50 tablets with a leaflet in a cardboard pack.

GRI 1 and 6

A drug in the form of a powder for the preparation of a suspension for oral administration (light brown powder with a fruity smell), containing in one bag: as an active ingredient - Saccharomyces boulardii CNCM I-745 lyophilisate 250.00 mg; as auxiliary substances - lactose monohydrate, fructose, silicon colloid dioxide, tutti-frutti flavoring.

Full description

It does not contain iodine or iodine compounds. It is used to treat and prevent diarrhea of any etiology in adults and children from 1 year old, including intestinal dysbiosis; acute infectious, viral or bacterial diarrhea; diarrhea caused by taking antibiotics; irritable bowel syndrome, enterocolitis, etc.

Packaged in packaging for retail sale. Release form: 10, 20, or 30 bags of 765 mg of the drug with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of capsules (solid gelatin capsules No. 3 with a cream body and an orange lid, the contents of the capsule are powder from white to creamy white, the formation of a cylindrical shape is possible, easily decaying when touched), containing in 1 capsule as the active substance: pyroxicam 20.0 mg, without iodine or iodine compounds.

Full description

It is used as a non-steroidal anti-inflammatory drug for symptomatic therapy of rheumatoid arthritis, ankylosing spondylitis (Bechterev's disease), osteoarthritis if it is impossible to use other drugs; It is intended to reduce pain and inflammation at the time of use.

Packaged in packaging for retail sale. Release form - 2 blisters of 10 capsules with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of a syrup (transparent, weakly viscous liquid with a specific raspberry smell), containing in 1 vial (100 ml) as the active ingredient: clenbuterol hydrochloride 0.0001 g, not containing iodine or iodine compounds.

Full description

It is used for symptomatic treatment of COPD (chronic obstructive pulmonary disease), bronchial obstructive syndrome, bronchial asthma.

Packaged in packaging for retail sale. Release form - 100 ml of the drug in a bottle with a measuring cup and instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of a solution for subcutaneous administration in a pre-filled disposable syringe (slightly opalescent solution from colorless to light yellow), containing in 1 ml of solution as an active substance - glatiramer acetate 40.0 mg, as auxiliary substances - mannitol 40.0 g, water for injection 944 mg, without iodine or iodine compounds.

Full description

It is used as an immunomodulating agent for remitting-recurrent multiple sclerosis.

Packaged in packaging for retail sale. Release form: 1 ml of solution in a disposable syringe of colorless glass with a plastic piston and a rubber piston seal, with a fixed needle protected by a double cap, in a contour cell package; 4 tapes of 3 contour cell packages with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of capsules (solid gelatin capsules No. 3 with a white body and a blue lid, the contents of the capsule are powder from white to creamy white, it is possible to form a cylindrical shape, easily decaying when touched), containing in 1 capsule as an active substance: pyroxicam 10.0 mg, not containing iodine or iodine compounds.

Full description

It is used as a non-steroidal anti-inflammatory drug for symptomatic therapy of rheumatoid arthritis, ankylosing spondylitis (Bechterev's disease), osteoarthritis if it is impossible to use other drugs; It is intended to reduce pain and inflammation at the time of use.

Packaged in packaging for retail sale. Release form - 2 blisters of 10 capsules with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of a solution for intramuscular administration (transparent colorless or slightly colored liquid with a brownish-yellow or greenish-yellow tint), containing in 1 ml of solution as active substances: metamizole sodium 500.0 mg, pitophenone hydrochloride 2.0 mg, fenpiverinium bromide 0.02 mg, not containing iodine or iodine compounds.

Full description

It is used for short-term symptomatic treatment of acute pain syndrome (weak or moderately pronounced) with spasms of smooth muscles of internal organs: gastric and intestinal colic, renal colic in renal stone disease, spasmodic dyskinesia of the biliary tract, algodismenorrhea.

Packaged in packaging for retail sale. Release form - 2 ml of solution in ampoules of neutral glass brown, 1 pallet of PVC film 10 ampoules with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of a solution for intramuscular administration (transparent colorless or slightly colored liquid with a brownish-yellow or greenish-yellow tint), containing in 1 ml of solution as active substances: metamizole sodium 500.0 mg, pitophenone hydrochloride 2.0 mg, fenpiverinium bromide 0.02 mg, not containing iodine or iodine compounds.

Full description

It is used for short-term symptomatic treatment of acute pain syndrome (weak or moderately pronounced) with spasms of smooth muscles of internal organs: gastric and intestinal colic, renal colic in renal stone disease, spasmodic dyskinesia of the biliary tract, algodismenorrhea.

Packaged in packaging for retail sale. Release form - 5 ml of solution in ampoules of neutral brown glass, 1 pallet of PVC film of 10 ampoules with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of tablets (round flat tablets with a chamfer and dividing risk on the one hand, white or almost white), containing in 1 tablet as an active ingredient: clenbuterol hydrochloride 0.02 mg, not containing iodine or iodine compounds.

Full description

It is used in adults and children from 6 years for the treatment of COPD (chronic obstructive pulmonary disease), bronchial obstructive syndrome, bronchial asthma.

Packaged in packaging for retail sale. Release form - 5 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of granules for the preparation of suspension for oral administration for children (granules: granules from white to almost white; suspension: opaque suspension from white to almost white), containing 1 g of granules as the active ingredient of 19.7 mg rivaroxaban (one bottle of 100 / 250 ml contains rivaroxaban micronized 51.7 / 103.4 mg; the concentration of rivaroxaban in the restored oral suspension is 1 mg / ml).

Full description

It does not contain iodine or iodine compounds. It is used to treat venous thromboembolism (VTE) and prevent recurrence of VTE in full-term newborns, infants, children and adolescents under the age of 18 years after at least 5 days of initial parenteral anticoagulant therapy.

Packaged in packaging for retail sale. Release form - 2.625 g of granules in a bottle of brown glass with a volume of 100 ml complete with 2 blue syringes with a volume of 1 ml with a calibration scale with a step of 0.1 ml, an adapter for the vial, with a water syringe of 50 ml with a calibration scale with a step of 1 ml or 5.25 g of granules in a bottle of brown glass with a volume of 250 ml complete with 2 blue syringes of 5 ml with a calibration scale with a step of 0.2 ml, 2 blue syringes of 10 ml with a calibration scale with a step of 0.5 ml, an adapter for the vial, water syringe with a volume of 100 ml with a calibration scale with a step of 2 ml with instructions for use and guidance for cooking in a cardboard pack.

GRI 3(b) and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания для детей (плоскоцилиндрической формы таблетки белого или почти белого цвета с фаской), содержащий в одной таблетке в качестве действующих веществ: Cypripedium parviflorum var. pubescens (Cypripedium pubescens)

Full description

D4 15,00 мг, Magnesium carbonicum D10 20,00 мг, Zincum valerianicum D12 15,00 мг; в качестве вспомогательных веществ: лактозы моногидрат, целлюлоза микрокристаллическая, тальк, магния стеарат, не содержащий йод или соединения йода. Применяется для лечения беспокойства и нарушения сна (трудности засыпания, беспокойный сон) у детей до 6 лет. Расфасован в упаковки для розничной продажи. Форма выпуска: по 150 таблеток во флаконе коричневого стекла с пластмассовой крышкой, с инструкцией по применению в картонной пачке.

GRI 1 and 6

Drug in the form of a solution for oral administration (light brown liquid with a fruity smell, opalescence is allowed, containing in 5 ml of the drug as an active component: ivy of ordinary leaves extract dry, ethanol extractant 30% (5 – 7.5): 1) - 35,000 mg; as auxiliary substances: water purified, potassium sorbate, citric acid is anhydrous, Sorbitol is liquid crystallizing, xanthanum gum, Frescofort Permasil, flavoring orange (natural), levomenthol, No iodine or iodine compounds.

Full description

It is used as an expectorant in the treatment of acute and chronic inflammatory diseases of the respiratory tract, accompanied by a cough with difficult to separate sputum.

Packaged in packaging for retail sale. Release form: 21 bags of 5 ml of the drug with instructions for use in a cardboard pack.

GRI 1 and 6

Гомеопатический лекарственный препарат в виде таблеток для рассасывания (таблетки плоскоцилиндрической формы белого или почти белого цвета с фаской), содержащий в одной таблетке в качестве активных компонентов: Luffa operculata(люффа оперкулата)

Full description

D4 – 25,0 мг, Galphimia glauca (галфимия глаука) D3 – 25,0 мг, Cardiospermum halicacabum (Cardiospermum) (кариоспермум халикакабум (кардиоспермум)) D3 – 25,0 мг; в качестве вспомогательных веществ: лактозы моногидрат, крахмал пшеничный, магния стеарат, не содержащий йод или соединения йода. Применяется для профилактики и лечения аллергических заболеваний верхних дыхательных путей: поллиноза, круглогодичного аллергического ринита (в комплексной терапии). Расфасован в упаковки для розничной продажи. Форма выпуска: по 5 блистеров по 20 таблеток с инструкцией по применению в картонной пачке.

GRI 1 and 6

Homeopathic medicinal product in the form of tablets for resorption for children (round tablets of white or almost white, with a chamfer), containing in one tablet as active components: Calcium carbonicum Hahnemanni D6 20.00 mg, Calcium fluoratum D6 20.00 mg, Calcium phosphoricum D6 20.00 mg, Sulfur jodatum D12 20.00 mg; as auxiliary substances: cellulose microcrystal, talc, magnesium stearate, not containing iodine or iodine compounds.

Full description

It is used to prevent SARS, accelerate recovery processes and increase the body's resistance to respiratory infections in frequently ill children under the age of 6 years. It has an independent therapeutic and prophylactic effect without the use of other drugs.

Packaged in packaging for retail sale. Release form: 150 tablets in a bottle of brown glass with a plastic cover, with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of drops for oral administration and inhalation (liquid of dark brown color with a characteristic smell), containing 1 ml (30 drops) of the drug as an active component: ivy of ordinary leaves dry extract, ethanol extract 30% (5 - 7.5 : 1) - 20.00 mg; as auxiliary substances: water purified, sodium saccharinate, ethanol 96%, anise of ordinary fruits oil, fennel of ordinary fruits, peppermint oil containing iodine or compounds.

Full description

It is used as an expectorant in the treatment of acute and chronic inflammatory diseases of the respiratory tract, accompanied by a cough with difficult to separate sputum.

Packaged in packaging for retail sale. Release form: 20 ml, 50 ml or 100 ml of the drug in a bottle of dark glass with a dropper cork and a screwing lid, with instructions for use in a cardboard pack.

GRI 1 and 6

The drug in the form of prolonged-release tablets coated with a film coating (round biconvex tablets coated with an orange-pink film shell, on a transverse incision, a grayish-white nucleus with interspersed yellow and white colors), weighing 374.50 mg each, is used to prevent iron deficiency conditions during pregnancy with insufficient iron intake from food, and treat iron deficiency anemia.

Full description

The composition of each tablet includes: active ingredient - iron sulfate 247.25 mg (in terms of iron (II) 80.00 mg); excipients - maltodextrin 25.00 mg (about 6.67 wt. %), cellulose microcrystalline 38.50 mg, methyl methacrylate, trimethylammonio-ethylmethacrylate chloride and ethylacrylate copolymer [2:0.2:1] (30% water dispersion) 5.85 mg, methyl methacrylate, trimethylammonio-ethylmethacrylate chloride and ethylacrylate copolymer [2:0.1:1] (30% water variance) 13.70 mg, triethyl citrate 3.90 mg, talc 7.80 mg, glyceryl dibegenate 8.00 mg.

Shell composition: Sepifilm® LP010 (methylhydroxypropyl cellulose (hypromellose), microcrystalline cellulose, stearic acid), triethyl citrate, iron oxide red, iron oxide yellow, titanium dioxide.

Packaged in packaging for retail sale. Release form - 3 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Veterinary medicinal product in the form of a gel for external use (homogeneous gel-like mass from white to cream color with the smell of menthol and camphor), containing in 1 ml as active substances: chondroitin sulfate 5.0 mg, glucosamine hydrochloride 5.0 mg, camphor 10.0 mg, levomenthol 10.0 mg; as auxiliary substances: dimethylsulfoxide, carbopol, triethanolamine, methylchloroisothiazolene, methione, water containing compounds.

Full description

It is used in horses independently or as part of the complex therapy of acute and chronic degenerative-dystrophic diseases of the musculoskeletal system of a localized form, including: arthritis, arthrosis, osteoarthritis, osteoarthritis, synovitis, tendovaginitis and bursitis, as well as for exacerbations of chronic diseases of the joints and tendons; to relieve the inflammatory process with significant loads, bruises, hematomas, myositis, sprains and ligaments.

Packaged in packaging for retail sale. Release form: 200 ml in a polymer bottle with instructions for use in a cardboard pack.

GRI 1 and 6

Bone graft substitute is a material in the form of a block with dimensions of 10 x 30 x 5 mm (D x X X X V) mm ± 5%, a volume of 1.5 cm3 (± 5%), a mass of 2.16 g (± 5%), designed to fill or reconstruct bone defects or gaps in the skeletal system that are not an integral part of bone structure stability.

Full description

Scope of application: traumatology, orthopedics, dentistry, spinal surgery. It can be used for bone defects resulting from injuries or surgically created defects of bones in the extremities, when filling cages in spinal surgery, scoliosis, increasing the area of the alveolar processes and the maxillary sinus. It is indicated for use in fractures with bone loss, limb fractures, non-healing fractures, tibial osteotomy, as well as arthrodesis (foot, ankle, hand, heel bone), sinus lifting, increased alveolar crest, interbody synthesis (cage), scoliosis.

The product of the porous structure consists of β-tricalcium phosphate (β-TCP, Ca3(PO4)2) with a density of 3.07 ± 0.1 g / cm3. Calcium phosphate structures are integrated into bone tissue due to their chemical composition, similar to the bone mineral phase, as well as their porosity, which ensures complete vascularization of the implant. The material is sterile, completely resorbed during the healing process, with direct contact with the patient's tissues, is biocompatible, X-ray contrast, avoids the use of autologous graft and pain in the area of graft collection.

The product in the amount of 5 pieces in one general sterile packaging for retail sale is intended for single use in standard operating conditions (only for single use).

GRI 1 and 6

Bone graft substitute - a material in the form of a paste in a ready-to-use 5 ml syringe in a volume of 3 cm3 (± 5%), consisting of particles of nano-hydroxyapatite dispersed in water, intended for use in the internal environment of the human body (injection paste, injected directly into the bone defect).

Full description

Hydroxyapatite, which is part of the material, is calcium phosphate, similar to human bone tissues in morphology and composition. Hydroxyapatite paste (Ca10(PO4)6(OH)2) is a homogeneous suspension of hydroxyapatite dispersed in water in a ratio of 35% hydroxyapatite, 65% water. The density of hydroxyapatite paste is 1.3 ± 0.1 g/cm3. The material has a high porosity and pore size of 350-500 microns, is designed to fill or reconstruct defects in the skeletal structure that are not inherent in the stability of the bone structure.

Scope of application: traumatology, orthopedics, dentistry, spinal surgery. It can be used for bone defects resulting from injuries or surgically created bone defects in the extremities, when filling cages in spinal surgery, increasing the area of the alveolar processes and the maxillary sinus, filling periodontal defects. It is indicated for use with non-healing fractures, an increase in the alveolar crest, as well as arthrodesis (foot, ankle, hand, heel bone), sinus lifting, interbody synthesis (cage), filling of cavities (benign tumors, cysts).

After placing the material to replace defects and restore bone tissue on the surface of the bone defect, it easily binds to the surface of the bone and forms strong chemical bonds with it, integrates, causing the formation and growth of bone tissue. At the same time, the material is absorbed under the action of the natural process of bone remodeling. As a result, the bone tissue is completely restored, and the material is replaced by the patient’s own bone. During the healing process, the material remains in the form of a soft gel and is not intended for use in places bearing a load, and is not used as a support structure of the skeletal structure.

The material is sterile, completely resorbed during the healing process, with direct contact with the patient, is biocompatible, X-ray contrast, avoids the use of autologous graft and pain in the area of graft sampling. The product in the amount of 1 piece in sterile packaging for retail sale is intended for single use in standard operating conditions (only for single use).

GRI 1 and 6

Bone graft substitute is a wedge-shaped material with dimensions of 20 x 15 x 12 mm (D x Sh x V) mm ± 5%, volume of 1.8 cm3 (± 5%), weight of 2.29 g (± 5%), designed to fill or reconstruct bone defects or gaps in the skeletal system that are not an integral part of bone structure stability.

Full description

Scope of application: traumatology, orthopedics, dentistry, spinal surgery. It can be used for bone defects resulting from injuries or surgically created defects of bones in the extremities, when filling cages in spinal surgery, scoliosis, increasing the area of the alveolar processes and the maxillary sinus. It is indicated for use in fractures with bone loss, limb fractures, non-healing fractures, tibial osteotomy, as well as arthrodesis (foot, ankle, hand, heel bone), sinus lifting, increased alveolar crest, interbody synthesis (cage), scoliosis.

The product of the porous structure consists of β-tricalcium phosphate (β-TCP, Ca3(PO4)2) with a density of 3.07 ± 0.1 g / cm3. Calcium phosphate structures are integrated into bone tissue due to their chemical composition, similar to the bone mineral phase, as well as their porosity, which ensures complete vascularization of the implant. The material is sterile, completely resorbed during the healing process, with direct contact with the patient's tissues, is biocompatible, X-ray contrast, avoids the use of autologous graft and pain in the area of graft collection.

The product in the amount of 1 piece in individual sterile packaging for retail sale is intended for single use in standard operating conditions (only for single use).

GRI 1 and 6

Homeopathic medicinal product in the form of granules (white granules of almost spherical shape, odorless, easily soluble in water), containing in 1 dose as active ingredients: Anas barbariaelium, hepatic et cordis extractum (anas barbarialium, hepatic et cordis extractum)

Full description

(extract of liver and heart of Barbary duck) 200 K 0.01 ml, not containing iodine or iodine compounds. It is used for the prevention and treatment of mild and moderate influenza, acute respiratory viral infection (ARVI). It has an independent therapeutic and prophylactic effect without the use of other drugs, and in combination with other drugs.

Packed in packaging for retail sale. Release form: 3 tubes of white polypropylene with a cork of 1 dose (1 gram) in 2, 4 or 10 blisters from a transparent polychlorine-vinyl thermal adhesive film with instructions for use in a cardboard pack.

GRI 1 and 6

Гомеопатическое лекарственное средство в виде мази для наружного применения (однородная мазь от жёлтого до жёлто-оранжевого цвета с характерным запахом), содержащее (на 100 г) активные компоненты: вазелиновый экстракт из смеси трех видов свежих растений Calendula officinalis (Календула лекарственная), Hypericum perforatum (Зверобой продырявленный), Achillea millefolium (Тысячеслистник) в соотношении 20:10:10 97,0 г, Ledum palustre MT (Багульник болотный, матричная настойка) 1,5 г, Pulsatilla MT (Прострел, матричная настойка) 1,5 г.

Full description

Применяется при ожогах 1-2 степени, поверхностных ранах (мелкие порезы, трещины, ссадины), укусы насекомых. Расфасовано в упаковки для розничной продажи. Форма выпуска: по 30 г мази в алюминиевой тубе с инструкцией по применению в картонной пачке.

GRI 1 and 6

Medication for veterinary use in the form of a solution for external use (transparent solution from colorless to yellow or brown), containing in 1 ml of solution as active substances - praziquantel 85.8 mg and emodepsid 21.4 mg (in 1 pipette of 0.7 ml of solution - praziquantel 60.0 mg, emodepsid 15.0 mg), as auxiliary substances: butylhydroxianizole, isopropylidene glycerin, lactic acid.

Full description

It is used in cats as a combined anthelmintic drug for the treatment and prevention of nematodeses (toxocariasis, toxascariasis, ankylostomosis, elurostrongilosis) and cestodoses (teniadose, dipilidiosis, echinococcosis). The pharmacokinetic properties of the drug provide good absorption from the site of application, long-term preservation in the therapeutic concentration in the animal.

Packaged in packaging for retail sale. Release form: 0.7 ml of solution in a polymer pipette with a cap, 1 pipette in a foil package with instructions for use in a cardboard pack.

GRI 1 and 6

Medication for veterinary use "..." in the form of a 12% solution for external use (a solution from colorless to yellow), containing in 1 ml of solution as an active substance - selamectin 120.0 mg (in 1 pipette of 2.0 ml of solution - selamectin 240.0 mg), as auxiliary substances: butyl hydroxytoluene, isopropyl mirist, isopropyl alcohol.

Full description

It is used in dogs for therapeutic and prophylactic purposes for entomosis caused by fleas, lice and lice-eaters, in the complex therapy of flea allergic dermatitis, as well as for the treatment of odectosis, sarcoptosis, toxocariasis and for the prevention of dirofilarosis. The pharmacokinetic properties of the drug ensure good absorption of selamectin from the site of application, long-term maintenance of therapeutic concentrations in the organs and tissues of the animal.

Packaged in packaging for retail sale. Release form: 2.0 ml of 12% solution in a polymer pipette with a green cap, 3 pipettes in a blister with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of a syrup (transparent, orange color, viscous liquid with a specific smell), containing in 10 ml as active substances: bromhexine hydrochloride 4 mg, guaifenesin 100 mg, salbutamol sulfate equivalent to salbutamol 2 mg, without iodine or iodine compounds.

Full description

It is used in adults and children aged 2 years for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 100 or 200 ml of syrup in a plastic bottle with a lid on which a plastic measuring cap is fixed, with instructions for use in a cardboard pack.

GRI 1 and 6

Veterinary medicinal product ".." in the form of tablets for oral administration (oval tablets from beige to brown with a dividing risk, an impression of "..." and the logo of the manufacturer, the presence of light and dark inclusions is allowed), containing in 1 tablet as an active substance: pimobendan 5.0 mg, as auxiliary substances: lactose monohydrate, microcrystalline cellulose, povidone, magnesium stearate, sodium crosscarmellose, anhydrous acid, citric acid, dioxide, cream containing beefodium, or beefodium compounds.

Full description

It is used in dogs for the treatment of heart failure caused by dilated cardiomyopathy (DCM) at the asymptomatic (preclinical) and clinical stages of the disease, as well as for myxomatous degeneration of bivalve (mitral) or tricuspid valve at the clinical stage and myxomatous degeneration of the mitral valve at the asymptomatic (preclinical) stage of the disease.

Packaged in packaging for retail sale. Release form: 50 tablets polymer cans with a screwing lid, with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of an oral solution (transparent, colorless or yellowish liquid with a characteristic odor), containing in 5 ml as active substances: bromhexine hydrochloride 2.0 mg, guaifenesin 50.0 mg, salbutamol sulfate 1.2 mg, equivalent to salbutamol 1.0 mg, without iodine or iodine compounds.

Full description

It is used in adults and children over 2 years of age for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 100 ml of solution in a plastic bottle with a lid and a measuring cup, with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of an oral solution (transparent, colorless or yellowish liquid with a characteristic odor), containing in 5 ml as active substances: bromhexine hydrochloride 2.0 mg, guaifenesin 50.0 mg, salbutamol sulfate 1.2 mg, equivalent to salbutamol 1.0 mg, without iodine or iodine compounds.

Full description

It is used in adults and children over 2 years of age for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 200 ml of solution in a plastic bottle with a lid and a measuring cup, with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of tablets (white, round, flat tablets with a chamfer and unilateral risk), containing in 1 tablet as active substances: bromhexine hydrochloride 8.00 mg, guaifenesin 100.00 mg, salbutamol sulfate equivalent to salbutamol 2.0 mg, not containing iodine or iodine compounds.

Full description

It is used for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 1 contour cell pack of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of tablets (white, round, flat tablets with a chamfer and unilateral risk), containing in 1 tablet as active substances: bromhexine hydrochloride 8.00 mg, guaifenesin 100.00 mg, salbutamol sulfate equivalent to salbutamol 2.0 mg, not containing iodine or iodine compounds.

Full description

It is used for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 2 contour cell packs of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of tablets (white, round, flat tablets with a chamfer and unilateral risk), containing in 1 tablet as active substances: bromhexine hydrochloride 8.00 mg, guaifenesin 100.00 mg, salbutamol sulfate equivalent to salbutamol 2.0 mg, not containing iodine or iodine compounds.

Full description

It is used for symptomatic therapy of productive cough associated with various respiratory diseases, including, among others, the following: acute bronchitis, chronic bronchitis without additional clarification (BDU), chronic obstructive pulmonary disease (COPD), asthmatic bronchitis, pneumonia.

Packaged in packaging for retail sale. Release form: 5 contour cell packs of 10 tablets, with instructions for use in a cardboard pack.

GRI 1 and 6

Medication for veterinary use "..." in the form of a 6% solution for external use (a solution from colorless to yellow), containing in 1 ml of solution as an active substance - selamectin 60.0 mg (in 1 pipette of 0.25 ml of solution - selamectin 15.0 mg), as auxiliary substances: butyl hydroxytoluene, isopropyl mirist, isopropyl alcohol.

Full description

It is used in dogs for therapeutic and prophylactic purposes for entomosis caused by fleas, lice and lice-eaters, in the complex therapy of flea allergic dermatitis, as well as for the treatment of odectosis, sarcoptosis, toxocariasis and for the prevention of dirofilarosis. The pharmacokinetic properties of the drug ensure good absorption of selamectin from the site of application, long-term maintenance of therapeutic concentrations in the organs and tissues of the animal.

Packaged in packaging for retail sale. Release form: 0.25 ml of 6% solution in a polymer pipette with a purple-red cap, 3 pipettes in a blister with instructions for use in a cardboard pack.

GRI 1 and 6

"Prosthetic synovial fluid" in the form of a disposable pre-filled syringe without a needle, containing a solution for intraarticular injections (viscoelastic, sterile and apyrogenic solution, It is composed of: active component - sodium hyaluronate (hyaluronic acid) 20 mg / ml (corresponding to a concentration of 2.0%) in sodium-phosphate buffer physiological solution (sodium chloride 0.7%), sodium dihydrophosphate (dihydrate 0.0014%), bibasic sodium phosphate (heptahydrate) 0.04%, water for injection up to 100%).

Full description

Designed for injection into the knee joint to restore the viscosity of synovial fluid, reduce the inflammatory response, protect the tissues of the joint, is intended for the treatment of pain in osteoarthritis of the knee for patients who have not shown an adequate response to conservative non-pharmacological treatment, as well as mild analgesics.

Packaged in packaging for retail sale. Release form - 3.0 ml of the drug in a disposable syringe without a needle in a plastic case with instructions for use and stickers for the patient (2 pcs) in a cardboard pack.

GRI 1 and 6

"Prosthetic synovial fluid" in the form of a disposable pre-filled syringe without a needle, containing a solution for intraarticular injections (viscoelastic, sterile and apyrogenic solution, It is composed of: active component - sodium hyaluronate (hyaluronic acid) 30 mg (corresponding to a concentration of 1.5%) in sodium-phosphate buffer physiological solution (sodium chloride 15.6 mg, sodium dihydrophosphate (dihydrate 0.028 mg), bibasic sodium phosphate (heptahydrate) 0.8 mg, water for injection up to 100%).

Full description

Designed for injection into the knee joint to restore the viscosity of synovial fluid, reduce the inflammatory response, protect the tissues of the joint, is intended for the treatment of pain in osteoarthritis of the knee for patients who have not shown an adequate response to conservative non-pharmacological treatment, as well as mild analgesics.

Packaged in packaging for retail sale. Release form - 2.5 ml of the drug in a disposable syringe without a needle in a plastic case with instructions for use and stickers for the patient (2 pcs) in a cardboard pack.

GRI 1 and 6

The drug "..." in the form of capsules (smooth shiny gelatin capsules No. 2 with a white case and a blue lid, the contents are white or white powder with a slight yellowish shade of color), containing in 1 capsule as the active ingredient of etifoxin hydrochloride 50.0 mg, as auxiliary substances: lactose monohydrate, talc, microcrystalline cellulose, colloid anhydrous silicon, magnesium stearate.

Full description

The composition of the capsule shell: titanium dioxide, gelatin, indigocarmine. It does not contain iodine or iodine compounds. It is used to treat anxiety and related psychosomatic disorders.

Packaged in packaging for retail sale. Release form: 2 blisters of 12 capsules or 3 blisters of 20 capsules with a leaf-inlay in a cardboard pack.

GRI 1 and 6

Drug in the form of ear drops (transparent, colorless or yellowish solution with the smell of alcohol), containing in 1 g of solution as active substances: lidocaine hydrochloride 10.0 mg and phenazone 40.0 mg, not containing iodine or iodine compounds.

Full description

It is used for local symptomatic treatment and anesthesia in children from birth and adults with otitis media with intact eardrum, including with: acute exudative otitis media; otitis, as a complication after influenza, exudative viral otitis; barotraumatic otitis.

Packaged in packaging for retail sale. Release form: 16 g of solution in a bottle with a leaf-inlay in a cardboard pack.

GRI 1 and 6

Drug in the form of a solution for infusions and intramuscular administration (transparent colorless solution without odor), containing in 1 ampoule (2 ml) as the active ingredient of nephopam hydrochloride 20.0 mg, not containing iodine or iodine compounds.

Full description

It is used for symptomatic treatment of acute pain syndrome, including postoperative pain.

Packaged in packaging for retail sale. Release form: 5 ampoules of 2 ml in a plastic pallet with instructions for use in a cardboard pack.

GRI 1 and 6

Medication for veterinary use in the form of a 6% solution for external use (transparent solution from colorless to yellow or brown), containing in 1 ml of solution as an active substance - selamectin 60.0 mg (1 pipette of 0.75 ml of solution - selamectin 45.0 mg), as auxiliary substances: isopropyl alcohol, butyl hydroxytoluene, dimethyl sulfoxide.

Full description

It is used in dogs and cats for the treatment and prevention of entomosis caused by fleas, lice and lice-eaters, odecosis, sarcoptosis, demodicosis, notohedrosis, ankylostomosis and toxocariasis, as well as for the prevention of dirofilariasis. The pharmacokinetic properties of the drug ensure good absorption of selamectin from the site of application, long-term maintenance of therapeutic concentrations in the organs and tissues of the animal.

Packaged in packaging for retail sale. Release form: 0.75 ml of 6% solution in a polymer pipette with a turquoise cap, 1 pipette in a three-layer bag of aluminum foil with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of drops for oral administration (transparent colorless or light brown solution), containing in 1 ml of solution as an active substance - cetirizine dihydrochloride 10.0 mg (in 1 drop of solution - 0.5 mg of cetirizine dihydrochloride), not containing iodine or iodine compounds.

Full description

It is used as an antihistamine in adults and children from 6 months to relieve: nasal and eye symptoms of year-round (persistent) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis - itching, sneezing, nasal congestion, abundant mucous discharge from the nose (rhinorrhea), lacrimation, redness of the mucous membrane of the eye (conjunctival hyperemia), symptoms of chronic idiopathic hives (itchy inflammation).

Packaged in packaging for retail sale. Release form: 10, 15, 20, 25 or 30 ml of solution in a bottle with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of a spray for topical use metered (transparent colorless liquid with a characteristic smell), containing 1 dose of spray as an active substance - benzidamine hydrochloride 0.255 mg (1 ml of the drug - 1.50 mg of benzidamine hydrochloride), not containing iodine or iodine compounds.

Full description

It is used in adults and children from 3 years old as symptomatic therapy of pain syndrome of inflammatory diseases of the oral cavity and ENT organs (various etiology): gingivitis, glossitis, stomatitis, pharyngitis, laryngitis, tonsillitis, etc.

Packaged in packaging for retail sale. Release form: 15, 20 or 30 ml of solution in a bottle with a pump and a pressure device with a folding cannula with instructions for use in a cardboard pack.

GRI 1 and 6

Drug in the form of nasal drops (transparent from colorless to light yellow solution), containing 1 ml as the active ingredient - oxymetazoline hydrochloride 0.500 mg, not containing iodine or iodine compounds.

Full description

It is used in adults and children aged 6 to 18 years with acute respiratory diseases with the phenomenon of rhinitis (rhinitis), acute allergic rhinitis, exacerbation of vasomotor rhinitis, to restore drainage with inflammation of the sinuses of the nasal cavity (sinusitis), Eustachitis, otitis media, to eliminate edema before diagnostic manipulations in the nasal passages.

Packaged in packaging for retail sale. Release form: 10 ml in a bottle with a dispenser nozzle for nasal use and a protective cap, with a leaflet in a cardboard pack.

GRI 1 and 6

Homeopathic medicine in the form of resorption tablets (round, flat-cylindrical tablets, with a risk on one side and a chamfer on both sides, white with a yellowish hue of color; fault line (risk) is not intended for breaking the tablet), containing in 1 tablet as active components: Phytolacca Americana (Phytolacca Americana) Ø 50 mg, Capsicum annuum (capsicum annuum)

Full description

D3 75 mg, Guaiacum (Guaicum) D3 75 mg, not containing compounds. It is used in adults in complex therapy as a symptomatic remedy for sore throat in acute inflammatory diseases of the throat.

Packaged in packaging for retail sale. Release form: 1, 2, 4 or 8 blisters of 25 tablets with a leaflet in a cardboard pack.

GRI 1 and 6

Medication in the form of capsules (elongated solid gelatin capsules No. 0 with a white opaque body and a white opaque cover; the contents of the capsules are a powdered mixture from white to almost white; on the capsule body on both sides in black ink is written "), containing in each capsule as an active substance - palovaroten 1.0 mg, not containing iodine or iodine compounds.

Full description

It is used to reduce the volume of new heterotopic ossification in adults and children (girls aged 8 years, boys aged 10 years) with ossifying progressive fibrodysplasia (FOP).

Packaged in packaging for retail sale. Release form: 2 blisters of 14 capsules with a leaf-inlay in a cardboard pack.

GRI 1 and 6

Drug in the form of a gel for external use (colorless or with a slightly yellowish tint, almost transparent gel of viscous consistency with a characteristic smell), containing 100 g of the drug: as an active substance - sodium heparin 0.83 g (1 g of the drug contains 1000 IU of heparin sodium); as auxiliary substances - carbomer 940, ethanol 96%, trolamine, methylparahydroxybenzoate, propylparahydroxybenzoate, lavender oil, water containing purified iodine and iodine compounds.

Full description

It is used as a direct anticoagulant agent for local use in diseases of superficial veins (varicose veins, chronic venous insufficiency and related complications), blunt injuries and bruises of soft tissues, subcutaneous hematomas (including hematomas after vein operations, phlebectomy), localized infiltrates and edema of soft tissues.

Packaged in packaging for retail sale. Release form: 40 g of the drug in a tube with instructions for use in a cardboard pack.

GRI 1 and 6

Homeopathic medicinal product in the form of drops for oral administration (transparent colorless or slightly light yellow liquid with a characteristic smell), containing in 100 g of the drug as active components: Anamirta cocculus D4 70 g, Petroleum rectificatum (Petroleum rectificatum)

Full description

D8 10 g, Ambra grisea (Ambra) D6 10 g, Conium maculatum (Conium) D3 10 g; as auxiliary substances: ethanol (ethyl alcohol) about 35% (by volume). It does not contain iodine or iodine compounds. It is used for the prevention and treatment of dizziness of various origins, including dizziness associated with motion sickness in transport.

Packaged in packaging for retail sale. Release form: 30 ml of the drug in a bottle, with instructions for use in a cardboard pack.

GRI 1 and 6

Medication in the form of a solution for oral administration (transparent colorless liquid), containing as an active substance: desloratadine (micronized) 0.5 mg, without iodine or iodine compounds.

Full description

It is used as an anti-allergic remedy for allergic rhinitis (elimination or relief of sneezing, nasal congestion, mucus secretion from the nose, itching in the nose, itching of the palate, itching and redness of the eyes, tearing) and hives (reducing or eliminating skin itching, rash).

Packaged in packaging for retail sale. Release form - 1 glass bottle of 30, 60 or 100 ml of solution, complete with a dosage spoon or syringe, graded to measure the required amount of the drug, with instructions for use in a cardboard pack.

GRI 1 and 6

A drug in the form of prolonged-release tablets coated with a film coating (circular biconvex tablets coated with an orange-pink film coating, a grayish-white nucleus with interspersed yellow and white color on a cross-section), containing in one tablet as an active substance: iron sulfate 247.25 mg (in terms of iron (II) 80.00 mg), without iodine or iodine compounds.

Full description

It is used in adults and children older than 6 years for the treatment of iron deficiency anemia, the prevention of iron deficiency conditions during pregnancy with insufficient intake of iron from food.

Packaged in packaging for retail sale. Release form - 3 blisters of 10 tablets with instructions for use in a cardboard pack.

GRI 1 and 6

Rulings of other EAEU countries for this code (624)

An advance ruling binds only the country that issued it, but it shows how neighbours in the Union classify this product.

The EEC publishes these rulings in Russian only, and they are shown as published.

Armenia

Жидкий имплантат торговой марки предназначен для лечения поражений межпозвоночных дисков шейного, грудного и поясничного отделов в ходе медицинских вмешательств.

Full description

Поставляется в виде набора, включающего в себя: стеклянный флакон объемом 3 мл с вязким раствором черного цвета (продукт на основе этилцеллюлозы, растворенной в этаноле, с добавлением частиц вольфрама размером до 100 нм, обеспечивающих рентгенконтрастные свойства) - 1 шт.; шприцы инъекционные объемом 1 мл - 3 шт.; иглы спинальные инъекционные - 3 шт.; руководство по эксплуатации - 1 шт. Перед применением содержимое флакона предварительно перемешивается до получения гомогенной массы для последующего введения в пульпозное ядро межпозвоночного диска.

Изделие упаковано в индивидуальную картонную коробку. Масса нетто: 250г.

Основные правила интерпретации 1, 3 (б) и 6 ТН ВЭД

Belarus

Ветеринарный препарат в форме раствора для орального применения от желтого до коричневого цвета, предназначенный для использования в качестве регидрационного средства при желудочно-кишечных болезнях у телят, сопровождающихся диареей, обезвоживанием и интоксикацией.

Full description

Состав: в 100 мл препарата в качестве действующих веществ содержится: 9,93г натрия (в форме натрия хлорида), 3,62г калия (в форме калия хлорида), 16,4г глюкозы (в форме глюкозы моногидрат и сиропа глюкозного) и 7,87 г хлоридов; вспомогательные вещества: натрия ацетат, натрия пропионат, глицин, натрия глутамат, ароматические вещества, вода очищенная. Препарат назначают животным перорально в следующей дозировке: 25 мл препарата растворяют в 1 литре теплого молока или питьевой воды, выпаивают по 1 литру два раза в сутки в течение 1-7 дней.

Расфасован по 500 мл во флаконах из полиэтилен- терефталата или полиэтилена высокой плотности и по 5 л в полимерных канистрах, флаконы и канистра имеют этикетку со следующей информацией: состав, показания к применению, дозировка препарата.

В соответсвии с ОПИ 1 и 6 ТН ВЭД ЕАЭС

Belarus

Дозированное лекарственное средство в форме таблеток.

Full description

Одна таблетка содержит 60 мг густого экстракта из листьев полыни Аржи (Artemisia argyi/ Artemisia princeps Pampanini), в состав которых входят активные вещества эупатилин 0,48-1,44 мг и яцеосидин 0,15-0,45 мг. Фармакотерапевтическая группа: другие препараты для лечения заболеваний, связанных с нарушением кислотности. Показания к применению: профилактика НПВС-индуцированных эрозивно-язвенных поражений желудка и 12-перстной кишки. Таблетки расфасованы по тридцать штук во флаконы из ПЭВП и помещены в картонную коробку вместе с инструкцией по медицинскому применению.

В соответствии с ОПИ 1 и 6, пояснения к товарной позиции 3004

EEC decisions on this code

Rates, trade defence measures, licensing and classification: decisions since 2016 whose text names code 3004900002.

Titles of acts are given in Russian as published: this is how they are cited in customs documents.

Duty rate, quotas and trade defence

  • Duties and rates

    Решение Совета ЕЭК № 13

    О внесении изменений в единую Товарную номенклатуру внешнеэкономической деятельности Евразийского экономического союза и Единый таможенный тариф Евразийского экономического союза, а также в решения Комиссии Таможенного союза в отношении отдельных товаров, предназначенных для кожевенно-обувной и химической промышленности, и в некоторые решения Высшего Евразийского экономического совета и Совета Евразийской экономической комиссии

    adopted Jan 30, 2026 · published Feb 26, 2026 · entered into force Mar 8, 2026

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 99

    О внесении изменений в перечень товаров, происходящих из развивающихся стран или из наименее развитых стран, в отношении которых при ввозе на таможенную территорию Евразийского экономического союза предоставляются тарифные преференции

    adopted Oct 5, 2021 · published Nov 8, 2021 · entered into force Jan 1, 2022

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 95

    О внесении изменений в перечень товаров, в отношении которых Республикой Казахстан в соответствии с обязательствами, принятыми в качестве условия присоединения к Всемирной торговой организации, применяются ставки ввозных таможенных пошлин, более низкие по сравнению со ставками пошлин Единого таможенного тарифа Евразийского экономического союза, и размеров таких ставок пошлин

    adopted Oct 30, 2020 · published Nov 11, 2020 · entered into force Dec 1, 2020

    Text of the act (opens in a new tab)
Show 6 more

  • Duties and rates

    Решение Коллегии ЕЭК № 61

    О внесении изменений в перечень товаров и ставок, в отношении которых в течение переходного периода Кыргызская Республика применяет ставки ввозных таможенных пошлин, отличные от ставок пошлин, установленных Единым таможенным тарифом Евразийского экономического союза

    adopted Apr 28, 2020 · published Apr 30, 2020 · entered into force May 30, 2020

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Коллегии ЕЭК № 62

    Об утверждении перечня товаров и ставок, в отношении которых в течение переходного периода Республикой Армения применяются ставки ввозных таможенных пошлин, отличные от ставок Единого таможенного тарифа Евразийского экономического союза

    adopted Apr 28, 2020 · published Apr 30, 2020 · entered into force Jun 12, 2020

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 109

    О внесении изменений в перечень товаров, в отношении которых Республикой Казахстан в соответствии с обязательствами, принятыми в качестве условия присоединения к Всемирной торговой организации, применяются ставки ввозных таможенных пошлин, более низкие по сравнению со ставками пошлин Единого таможенного тарифа Евразийского экономического союза, и размеров таких ставок пошлин

    adopted Dec 19, 2019 · published Dec 24, 2019 · entered into force Jan 3, 2020

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 44

    О внесении изменений в перечень товаров, в отношении которых Республикой Казахстан в соответствии с обязательствами, принятыми в качестве условия присоединения к Всемирной торговой организации, применяются ставки ввозных таможенных пошлин, более низкие по сравнению со ставками пошлин Единого таможенного тарифа Евразийского экономического союза, и размеров таких ставок пошлин

    adopted Apr 29, 2019 · published May 6, 2019 · entered into force May 16, 2019

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 18

    О внесении изменений в перечень товаров, в отношении которых Республикой Казахстан в соответствии с обязательствами, принятыми в качестве условия присоединения к Всемирной торговой организации, применяются ставки ввозных таможенных пошлин, более низкие по сравнению со ставками пошлин Единого таможенного тарифа Евразийского экономического союза, и размеров таких ставок пошлин

    adopted Jan 26, 2018 · published Mar 27, 2018 · the entry into force date is set in the text of the act

    Text of the act (opens in a new tab)

  • Duties and rates

    Решение Совета ЕЭК № 8

    О перечне товаров, происходящих из развивающихся стран или из наименее развитых стран, в отношении которых при ввозе на таможенную территорию Евразийского экономического союза предоставляются тарифные преференции

    Amends: О едином таможенно-тарифном регулировании таможенного союза Республики Беларусь, Республики Казахстан и Российской Федерации

    adopted Jan 13, 2017 · published Feb 28, 2017 · entered into force Aug 28, 2017

    Text of the act (opens in a new tab)

Other decisions

  • Labelling

    Решение Совета ЕЭК № 108

    О маркировке лекарственных препаратов средствами идентификации

    The decision names not this code but heading 3004: it covers all codes under it.

    adopted Sep 27, 2023 · published Oct 10, 2023 · entered into force Nov 9, 2023

    Text of the act (opens in a new tab)

  • Customs operations

    Решение Совета ЕЭК № 37

    О внесении изменений в некоторые решения Комиссии Таможенного союза и об утверждении перечней товаров, ввозимых на таможенную территорию Евразийского экономического союза в целях реализации мер, направленных на повышение устойчивости экономик государств – членов Евразийского экономического союза

    adopted Mar 17, 2022 · published Mar 18, 2022 · entered into force Mar 28, 2022

    Text of the act (opens in a new tab)

  • Classification

    Решение Коллегии ЕЭК № 38

    О классификации препаратов, содержащих депротеинизированный гемодиализат из крови телят, в соответствии с единой Товарной номенклатурой внешнеэкономической деятельности Евразийского экономического союза

    adopted Mar 30, 2021 · published Apr 2, 2021 · entered into force May 2, 2021

    Text of the act (opens in a new tab)
Show 4 more

  • Classification

    Решение Коллегии ЕЭК № 166

    О классификации препаратов для лечения угревой сыпи в соответствии с единой Товарной номенклатурой внешнеэкономической деятельности Евразийского экономического союза

    The decision names not this code but heading 3004: it covers all codes under it.

    adopted Dec 8, 2020 · published Dec 9, 2020 · entered into force Jan 8, 2021

    Text of the act (opens in a new tab)

  • Classification

    Решение Коллегии ЕЭК № 63

    О классификации препаратов для лечения заболеваний дыхательных путей в соответствии с единой Товарной номенклатурой внешнеэкономической деятельности Евразийского экономического союза

    The decision names not this code but heading 3004 90 000: it covers all codes under it.

    adopted Apr 24, 2018 · published Apr 27, 2018 · entered into force May 27, 2018

    Text of the act (opens in a new tab)

  • Classification

    Решение Коллегии ЕЭК № 126

    О классификации противовирусного препарата для лечения ВИЧ-инфицированных пациентов в соответствии с единой Товарной номенклатурой внешнеэкономической деятельности Евразийского экономического союза

    The decision names not this code but heading 3004: it covers all codes under it.

    adopted Sep 26, 2017 · published Sep 28, 2017 · entered into force Oct 28, 2017

    Text of the act (opens in a new tab)

  • Classification

    Решение Коллегии ЕЭК № 17

    О классификации имплантата для внутрисуставного введения по единой Товарной номенклатуре внешнеэкономической деятельности Евразийского экономического союза

    The decision names not this code but heading 3004: it covers all codes under it.

    adopted Feb 9, 2016 · published Feb 10, 2016 · entered into force Apr 10, 2016

    Text of the act (opens in a new tab)
All changes by weekFollow changes for this code

The right code is in the HS code search.